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Abstract 
During the course of this study, Tongan marine organisms were investigated for new 
secondary metabolites. A combination of reversed- and normal-phase chromatographic 
techniques and NMR spectroscopy was employed, to aid in the isolation and structure 
elucidation of the five known and four new compounds isolated in this study. 
A brief investigation into the antifungal activity of Tongan holothurian saponins was 
instigated in order to compare the activity against saponins isolated from the common New 
Zealand sea cucumber, Australostichopus mollis. A yeast-based chemical genetics study, 
determined the antifungal activity, for four partially purified Tongan holothurian extracts, 
against Saccharomyces cerevisiae, to be similar to neothyonidioside (44), a saponin from A. 
mollis. This result suggested the antifungal activity to be a common characteristic to sea 
cucumber saponins. 
Further interest in secondary metabolites from Tongan marine organisms led this study 
towards the investigation of Tongan marine sponges. Five sponges were selected for 
screening, and two chosen for further study which yielded five known compounds (51–53, 
61, 62) and four new fascaplysin derivatives; 7-bromoreticulatine, 
10-bromo-6,7-dimethoxyhomofascaplysin C, 10-bromo-6,7-dimethoxyhomofascaplysin D, 
and 10-bromohomofascaplysin A (63–66, respectively).  
Although 63 and 66 are new members of the fascaplysin family solely due to the position of 
the bromine, it appears that bromination on the A-ring is comparatively rare, with only three 
of the 24 literature examples displaying A-ring bromination. On the other hand, 64 and 65 
present a new sub-class of fascaplysin derivatives due to the presence of a dimethoxy 
functionality. Both 7-bromoreticulatine (63) and 10-bromohomofascaplysin A (66) were 
found to be potently cytotoxic in the HL-60 cell line, exhibiting IC50 values of 33.8 and 498 
nM, respectively. 10-Bromo-6,7-dimethoxyhomofascaplysins C (64) and D (65) were 
significantly less cytotoxic with respective IC50 values of 2.7 and 6.0 M. 
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Chapter 1 
Introduction 
1.1 Chemical History of Natural Products 
Historically, mankind has exploited and relied on natural resources for clothing, shelter 
foodstuffs, and perhaps the most intriguing, for medicines. Plants have been utilised as a 
major source for traditional medicines for thousands of years. The earliest ancient Egyptian 
medicine dates back to 2900 BC, although the “Ebers Papyrus”, dating from 1500 BC 
represents the most notable Egyptian pharmacopoeia documenting over 700 “drugs”. It was 
not until the 1800s, however, that the plant components responsible for the remedy of 
human illness were actively sought and in 1826 morphine (1) became the first commercially 
available pure natural product.1 These naturally-derived, biologically active compounds are 
now known to be secondary metabolites; chemical substances not essential to life as they are 
not required for the normal growth, development or reproduction of an organism.2 Initially 
regarded as waste products, these complex and frequently toxic chemicals are recognised as 
a means for interactions between organisms, often for defense.3 Ever since, secondary 
metabolites have captivated natural products chemists, who continue to pursue these 
fascinating molecules for both their interesting chemical structures and their potential as 
therapeutic agents for the treatment of human disease.  
 
 1 
 2 
 
Since initial investigations in the early 1800s, natural products chemistry has been 
fundamental to drug discovery and development, with plant and microbial derived drugs 
constituting a crucial role in the increased average human life span during the 20th century 
alone.4 The renowned antibiotic, penicillin G (2) and the chemotherapeutic drug, paclitaxel 
(Taxol, 3), are two such examples of medically important, naturally-derived drugs. Alexander 
Fleming’s discovery of penicillin G (2) from Penicillium notatum in 1928 incited extensive 
microbial natural products research between the 1940s and 1970s. Microbes were found to 
be prolific producers of antibiotic compounds, providing a vast number of structurally 
diverse bioactive metabolites.1, 4 Many of these microbial derived antibiotics still hold 
significance in the pharmaceutical industry, although the emergence of new pathogens and 
the continual development of drug-resistant bacteria drives the search for new antibacterial 
agents.5 Paclitaxel (3), originally isolated from the stem bark of the Western Yew tree, Taxus 
brevifolia, is an antitumour agent used in the treatment of ovarian, breast, lung and prostate 
cancer.6 Specific parts of a variety of species within the genus Taxus were used historically by 
several Native American tribes in their traditional medicines.1 The road to pharmaceutical 
success for Taxol (3) was lengthy, taking 21 years before the U.S Food and Drug 
Administration (FDA) approved the drug for clinical use.6b Between 1981 and 2008, almost 
two thirds of drugs approved by the FDA were natural products or derivatives thereof.3  
  
   
Despite the successful contribution of natural products research to medicine, many 
pharmaceutical companies began to downsize or completely dismantle their natural products 
facilities in the early 1990s.7 Combinatorial chemistry† was introduced as a faster and 
cheaper alternative to natural products isolation, and thus was rapidly embraced by the 
pharmaceutical industry.8 By the early 2000s, however, researchers were met with 
disappointment as combinatorial chemistry failed to provide the anticipated number of drug 
                                                   
† Combinatorial chemistry in its origin involved the use of a single compound in a variety of reactions in 
order to synthesise every possible combination of compounds that could be produced from it. 
2 3 
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leads.9 Attempts to build large libraries containing thousands to millions of synthetic 
compounds (high-throughput screening) using a single scaffold‡, often resulted in simplistic 
and topologically similar compounds, very few of which were biologically active.9, 10 Only 
one drug resulting from this method has been reported; sorafenib mesylate (Nexavar, 4), 
approved by the FDA in 2005 as an antitumour drug used for the treatment of advanced 
renal cancer.11 The concept of combinatorial chemistry has since shifted towards the 
production of small to medium-sized libraries, using multiple scaffolds. This amendment 
recognises the significance of natural products, as researchers aim to synthesise compounds 
which are more “natural product-like” using scaffolds based on biologically active, naturally-
derived compounds.10, 11  
 
While the modified method is expected to be more productive than its earlier version, the 
lack of success from combinatorial chemistry has begun to steer pharmaceutical companies 
back towards natural product discovery programmes.12 Certainly, technological 
advancements in isolation and spectroscopic techniques have made experimental analyses of 
natural products easier to carry out and interpret and have further contributed to the 
resurgence of interest in natural products research. For instance, a modern nuclear magnetic 
resonance (NMR) instrument can now routinely provide excellent data with sub-milligram 
samples.13 
1.2  The Marine Environment and Marine Natural Products 
The therapeutic use of medically important drugs such as morphine, penicillin, quinine, 
digitoxin, and aspirin demonstrates the important role plants and micro-organisms have 
played in medicine and indeed in the increased human life expectancy observed today.14 
Much potential remains to be offered by the terrestrial environment in the search for 
biologically active metabolites, although the advent of SCUBA (self-contained underwater 
breathing apparatus) has enabled explorations to extend into the marine environment. 
Marine environmental conditions are considerably different to terrestrial environments and 
it was assumed that the chemical characteristics of compounds from marine organisms 
would also be different.7  
                                                   
‡ A compound used as a template for the development of compound libraries in combinatorial chemistry. 
4 
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The oceans cover more than two thirds of the Earth’s surface and approximately 90% of the 
world’s species are represented in the marine environment.15 Experts estimate that certain 
marine ecosystems, such as coral reefs, contain a greater level of biological diversity than 
tropical rainforests.16 This large marine biodiversity, the majority of which is found within 
the ocean fringe, has led to the assumption of a high chemical diversity of secondary 
metabolites. Much of the marine life consists of soft-bodied, sessile or slow-moving 
organisms which have either acquired toxic secondary metabolites from marine micro-
organisms, or have evolved to biosynthesise them.16a These organisms utilise the compounds 
to paralyse prey, deter predators, or keep competitors at bay.17 Not surprisingly, marine-
derived toxins are often potent since they are rapidly diluted upon release.17 Chemical 
diversity, high toxicity, and not to mention the unique and often complex chemical structures 
are factors which contribute to the promising biological activities displayed by marine-
derived metabolites, hence their pursuit by marine natural product researchers.18 
Spongothymidine (5) and spongouridine (6), discovered in the 1950s by Bergmann and co-
workers from the Caribbean sponge Tethya crypta, are believed to be the earliest marine-
derived natural products reported.19 Further interest led to compounds 5 and 6 being used as 
prototypes for the development of the anti-HIV compound azidothymidine (AZT, 7), the 
antiviral drug adenine arabinoside (Vira-A, 8), and the anticancer agent cytosine arabinoside 
(Cytosar-U, 9).20 Although the discovery of compounds 5 and 6 prompted the interest of 
other natural products researchers, it was not until the 1970s when the marine environment 
was more seriously considered as a resource for potentially useful natural products and the 
term marine natural products was formally coined.16b, 21 
    
  
 
 
The marine environment has since proved to be a very fruitful resource for the isolation of 
many interesting biologically active compounds. Before 1995, approximately 6,500 
marine-derived compounds had been isolated;17 that figure has increased almost four-fold to 
more than 24,000.22 Some examples of interesting molecules from marine organisms include 
maitotoxin, palytoxin and symbiodinolide (10–12 respectively). With remarkably complex 
chemical architectures, compounds 10–12 are among the most extraordinary of those 
5 R = OH  R1 = OH R2 = CH3 
6 R = OH  R1 = OH  R2 = H 
7 R = N3 R1 = H  R2 = CH3 
8 9 
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isolated from nature. They are commonly referred to as “super carbon-chain compounds” as 
a result of their highly oxygen-functionalised, long-chain carbon backbone and are 
purported to be the largest natural products isolated besides biopolymers such as nucleic 
acids, proteins and polysaccharides. Maitotoxin (10), and palytoxin (11) induce extreme 
toxicity in mice, while symbiodinolide (12) exhibits biological activity against human 
neuroblastoma cells.23  
Currently, ten marine natural products (or derivatives thereof) are at various stages of 
clinical development, while ziconotide (Prialt, 13), trabectedin (Yondelis, 14), and eribulin 
mesylate (Halaven, 15) join compounds 7–9 in the ensemble of approved marine-derived 
pharmaceuticals.24 Ziconotide (13) is the synthetic equivalent of the 25-amino acid peptide, 
ω-conotoxin MVIIA which was isolated from the marine cone snail, Conus magus. Approved 
by the US FDA in 2004, 13 is a potent analgesic presently used for the management of 
chronic pain in cancer and AIDs patients and is considered more effective than opiates as the 
patient does not develop a dependency.25 Trabectedin (14), a tetrahydroquinoline alkaloid, 
was isolated from the tunicate, Ecteinascidia turbinata. In 2007, the European Union 
approved 14 for use against soft tissue carcinoma.25 The most recent addition, eribulin 
mesylate (15) is derived from halicondrin B (16), a marine natural product originally isolated 
from the sponge Halichondra okadai.24, 26 Eribulin mesylate (15) is approved for the 
treatment of metastatic breast cancer.27  
 10 
 6 
 
 
 
 
 
 
 
 
   
11 
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1.3 Marine Sponges 
Among the variety of marine organisms noted for producing secondary metabolites, sponges 
are a particularly prolific source of chemically diverse, biologically active compounds.28 The 
emergence of novel sponge metabolites remains steady, constituting close to 30% of marine 
natural products described between 2008 and 2010.29  
Sponges are multicellular, filter feeding organisms lacking true tissue organisation which 
places them among the most primitive of animals. The phylum Porifera is made up 
exclusively by sponges, containing the three classes Hexactinellida, Calcarea and the largest, 
Demospongiae, which comprises around 90% of sponge species. Sponges are taxonomically 
classified depending on morphological features and the types of spicules (skeletal element) 
present within the sponge; some sponges lack spicules which can cause difficulty when 
taxonomic classification is concerned. There are currently around 15,000 extant species and 
it is believed another 30,000 are yet to be described.30  
Sponges are soft bodied sessile organisms, that produce toxic or distasteful secondary 
metabolites to deter predators, keep neighbouring competitors at bay, or prevent parasitic 
infection or overgrowth of fouling organisms.28 A greater frequency of toxic compounds 
have been isolated from sponges that occupied space in a competitive environment or those 
that inhabited areas exposing them to predators. For example, sponges within coral reefs, 
where the level of biodiversity is high, often yield bioactive metabolites.31 Temporal and 
spatial variations have also been found to contribute to the concentration of mycalamide A 
(17) in Mycale hentsheli and salicylihalamide A (18) in Haliclona sp.32, 33 Sponges from 
tropical environments where more predation occurs and temperatures are warmer, have 
been found to contain high concentrations of toxic secondary metabolites.34, 35 The reason for 
this phenomenon is uncertain, but it is proposed that predation and competition pressures 
cause an increased investment by the sponge, into the production of chemical defences, thus 
resulting in increased levels of toxic metabolites in tropical sponges.31, 34, 35 Regardless, there 
is no doubt that sponges as a whole, have given rise to a variety of natural products which 
16 
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exhibit a wide range of biological activities from antitumour, antiviral, and anti-
inflammatory to immunosuppressive and neurosuppressive activity, all of which have 
potential as pharmaceuticals.20a, 29a, 29b, 36  
 
   
1.4 Sea Cucumbers 
Sea cucumbers (holothurians) belong within the phylum Echinodermata, which also includes 
organisms such as star fish and sea urchins. The phylum contains six extant orders of 
holothurians and approximately 1300 species, widespread throughout the world’s oceans. In 
90% of sea cucumbers, the endoskeleton is reduced to microscopic skeletal structures called 
ossicles, which are embedded in the dermis. Typically composed of calcium carbonate, ossicle 
shapes vary quite remarkably and are species specific which can be used to assist with 
taxonomic classification of holothurians.37  
As slow moving organisms, sea cucumbers are susceptible to predation and are therefore 
equipped with defensive mechanisms to aid in their survival. Physical defences can include 
the expulsion of strong adhesive threads (Cuvierian tubules) that act to instantly foul any 
object, and the evisceration and rapid regeneration of body organs.38 Often, these physical 
defences are complemented by chemical defences in the form of toxic secondary 
metabolites.37, 39 The most commonly found secondary metabolites from sea cucumbers are 
saponins; high molecular weight compounds consisting of a sugar moiety bound to an 
aglycon usually referred to as the genin or sapogenin.40 The term ‘saponin’ results from their 
surfactant properties, as they typically exhibit detergent-like characteristics such as the 
ability to cause foaming in water.41 Saponins can be found in all parts of the body within sea 
cucumbers.42  
Depending on the type of aglycon present, saponins can be grouped into three main classes–
steroid glycosides, steroid-alkaloid glycosides, and the most predominantly isolated, 
triterpene glycosides.41, 43 The earliest sea cucumber saponin described in the literature is the 
17 18 
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triterpene glycoside, holothurin A (19).44 Isolated in 1959 from Actinopyga agassizi, 19 has 
been found to possess neurolytic, hemolytic, and cancerostatic properties.44 Two decades 
later, holothurin B (20) was reported as an isolate from the sea cucumber Holothuria 
luecospilota Brandt.45 Recent examples of biologically active triterpene glycosides from sea 
cucumbers are pentactasides B (21) and C (22), isolated from Pentacta quadrangularis. These 
compounds displayed moderate in vitro cytotoxicity against a range of human cancerous cell 
lines.46 
 
 
 
 
  
1.5 The Kingdom of Tonga and Marine Natural Products 
Tropical sponges produce higher quantities of secondary metabolites compared with those 
from temperate environments.34, 35 This has certainly been observed for samples obtained 
19 
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from Tongan marine organisms in the MNP laboratory (VUW), to quite a significant degree 
when compared against New Zealand marine natural products. As mentioned earlier, 
competition and predation pressures are thought to contribute to this phenomenon.31, 35, 34, 72 
Located in the South Pacific Ocean, north-east of New Zealand, the Kingdom of Tonga is an 
archipelago with an Exclusive Economic Zone (EEZ) of approximately 700,000 km2. This 
large area encompasses 171 islands, of which only 48 are inhabited and is divided into five 
main groups: Vava’u, Tongatapu, ‘Eua, Ha’apai and the Nuias (Figure 1.1).  
 
Figure 1.1. Map of the Kingdom of Tonga. Courtesy of the University of Texas Austin 
Libraries. 
The literature documents many reports by leading MNP researchers of secondary metabolites 
from Indo-Pacific marine organisms but very few are reported from Tongan waters. 
Additionally, those which describe metabolites from Tongan marine organisms are from the 
1980s and methods of isolation were typically bioassay guided.47 The bioassay guided 
method of natural products isolation is target specific, homing in on the compound or 
compounds exhibiting activity in the particular assay used while neglecting all others. This 
means that many other minor, potentially biologically active chemical constituents may have 
been overlooked. As such, further investigations using the NMR screening methods employed 
by the VUW MNP laboratory (see Chapter 1.6) are justifiable as there remains potential for 
the discovery of new compounds. 
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Crews and Quin oa  reported the collection of a Psammaplysilla sp. from Tonga and the 
subsequent isolation of 3-bromo-4-hydroxyphenylacetonitrile (23) and psammaplin A (24)–
a compound which exhibits in vitro cytotoxicity in mice.48 Psammaplin A (24) was described 
as the first disulfide compound isolated from marine biota. Methyl nuapapuanoate (25) was 
isolated from a Prianos sp. collected from Tongan coral reefs and is believed to be the first 
report of a norditerpene from sponges.47 A Tongan collection of the sponge Hyrtios erecta 
yielded the norsesterterpenoid hyrtial (26) along with several scalarane sesterterpenes (27–
35).49, 50   
Investigations into Tongan marine natural products chemistry, by members of the VUW MNP 
research group, have led to the isolation of a variety of interesting biologically active 
secondary metabolites. A study of a Plakortis sp. sponge, resulted in the isolation of seven new 
polyketides, lehualides E–K (36–42).51 Lehualides I (40) and J (41) present a methyl sulphide 
and methyl sulfoxide functionality, respectively and are believed to be the first report of such 
moieties within isolates from the Plakortis genus. Lehualides F (37), G (38) and I (40) 
inhibited the growth of drug-sensitive mutant strains of Saccharomyces cerevisiae (bakers 
yeast) at 100 M concentrations, but were inactive against wild-type yeast. Compounds 
37-40 were also tested against the human promyelocytic leukemia (HL-60) cell line and 
were found to exhibit cytotoxicity with IC50 values of 6.2, 5.4, 14.6 and 10.8 M, 
respectively.51 An investigation of the sponge Cacospongia mycofijiensis yielded zampanolide 
(43),52 although 43 was originally reported from a Japanese collection of the sponge 
Fasciospongia rimosa in 1996.53 As a result of this recent isolation, 43 was discovered to be a 
microtubule stabilising agent, after exhibiting potent cytotoxicity against the HL-60 
(IC50 4.3 nM) and 1A9 (ovarian carcinoma; IC50 14.3 nM) cell lines. Interestingly, 43 was 
found to be equally cytotoxic as paclitaxel (3) against the A2780 (ovarian cancer) cell line 
(IC50 7.1 nM) and remained cytotoxic against the paclitaxel-resistant A2780AD cell line 
(IC50 7.5 nM).52 
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1.6 Targeting and Isolating Secondary Metabolites 
As secondary metabolites are not essential to life and are metabolically expensive to produce, 
they are often present within the manufacturing organism in low quantities. Generally, crude 
extracts of a given organism contain a large range of non-polar and polar materials54 which 
constitute high concentrations of primary metabolites and salts, and only low concentration 
35 
36 R = CH3 
37 R = H 
38 
 
39 R = CH3C(O) 
40 R = CH3 
41 
 
42 
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of secondary metabolites. Secondary metabolites typically comprise both polar and non-polar 
functionalities, essentially giving them an amphiphilic nature. This allows the compounds to 
transverse hydrophilic and hydrophobic environments, enabling partial solubility in water 
and more importantly in terms of biological activity, the ability to transport across the cell 
membrane to interact with the substrate.55  
Due to the vast array of compounds (possessing a range of polarities) present in a crude 
extract, solubility issues are often encountered. Thus, preliminary purification steps are 
common practice in a natural products laboratory before screening a crude extract. The 
hypothetical diagram shown in Figure 1.2 illustrates the relative masses of compounds 
within a crude extract, against the elution profile from reversed-phase column 
chromatography. A large proportion of the mass elutes from the column at the beginning 
(high polarity compounds such as carbohydrates) and the end (low polarity compounds such 
as lipids and steroids). The intermediate region or ‘mass window’ implicated in Figure 1.2, 
tends to contain the compounds of interest (i.e. secondary metabolites) and therefore provides 
an ideal target in preliminary purification stages of a crude extract.  
 
Figure 1.2. Schematic showing the mass distribution in a typical marine sponge extract. 
Liquid-liquid Partitioning 
The isolation of natural products typically comprises a variety of separation techniques, 
which depend on a range of factors such as solubility, stability, and volatility of the 
compounds to be separated. Liquid-liquid partitioning is one of the most commonly used 
methods for the fractionation of crude extracts. The method employs the use of two 
immiscible solvents, increasing the polarity at each subsequent step, as the process is carried 
out. Separation is achieved by distribution of the compounds into the different fractions 
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according to their polarity.54, 56 Although this technique is straightforward and has been used 
successfully, it requires large volumes of solvents, many of which are environmentally 
unfriendly, such as halogenated solvents. Furthermore, some extracts may form stable 
emulsions, leading to incomplete partitioning of the extract and target compounds can 
spread out into multiple fractions, introducing additional complications in the purification 
process.56  
Column Chromatography 
Column chromatography is a universal purification method used in natural products 
laboratories. Normal-phase column chromatography is a technique best suited for the 
separation of non-polar compounds. Once the sample has been loaded onto the column, 
elution is carried out beginning with a non-polar solvent and the polarity of the mobile 
phase is gradually increased with incremental additions of a polar solvent. Usually, silica gel 
is used in normal phase chromatography.17 In the case of medium to high polarity 
compounds, however, silica gel is problematic; owing to the polarity and Brønsted acidity of 
the silanol groups, polar compounds often irreversibly bind to, or chemically react with the 
sorbent. Consequently, separation and product recovery is often very low.57 Functionalised 
silica can provide additional benefits which help to overcome this problem. 
The efficient separation of medium to highly polar compounds can be carried out using 
reversed-phase column chromatography. Octadecyl derivatised silica gel (C18) is an example 
of a reversed-phase stationary medium initially used by Blunt et al. for the fractionation of a 
sponge extract.56 The crude extract is mixed with a small amount of C18 sorbent and 
concentrated under reduced pressure. Once dry, it is then transferred as a slurry onto a 
column containing C18 and eluted with solvent mixtures of decreasing polarity.56 As with 
normal-phase silica gel, this chromatographic technique also has its limitations. Repeated 
use, particularly with highly aqueous solutions, tends to ‘strip’ the octadecyl chains from the 
column, thereby exposing silanol groups to the sample.58 
Cyclic Loading 
Cyclic loading (Figure 1.3), developed by Northcote and West at Victoria University of 
Wellington (VUW), is a technique used for the fractionation of crude extracts from marine 
organisms.57 The technique uses poly(styrene-divinylbenzene) (PSDVB) as the stationary 
phase and like C18, is also a reversed-phase solid support, though it has many more 
advantages. PSDVB is a cross-linked polymer with a large surface area. Adsorption and 
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retention of compounds can be controlled by the use of ionic buffers, as PSDVB is stable 
throughout the pH range. The absence of surface ligands eliminates any possibility of 
‘stripping’ (as in C18) and therefore it remains chemically stable in aqueous solvents. As such, 
it can be reused repeatedly without concern. The use of inexpensive environmentally friendly 
solvents, such as acetone and methanol, is a further advantage. Concentration of crude 
extracts for loading onto columns is often problematic due to the broad mixture of polarities 
contained within; polar solvents cause non-polar compounds to precipitate out while non-
polar solvents have the opposite effect. The cyclic loading technique circumvents this issue by 
enabling an extract to be loaded directly onto the column without the need for pre-
concentration.  
When a crude extract is passed through the column containing PSDVB, most non-polar 
compounds adsorb to the stationary phase. The eluent is diluted with H2O (typically 100% 
v/v) and recycled through the column – this step is repeated until a three-fold dilution of the 
extract has been achieved. Addition of H2O increases the polarity of the eluent and thus each 
‘cyclic loading’ step means the compounds of slightly higher polarity (than those already 
adsorbed onto PSDVB) will have a greater affinity for the stationary phase, ensuring 
adsorption of these compounds. Elution of the column is sequentially carried out with 
organic modifier/H2O mixtures of decreasing polarity.  
Although the cyclic loading process is relatively straightforward, the resulting fractions 
containing water have a tendency to froth when concentrating under reduced pressure. A 
modified cyclic loading process described as back loading, is next employed to remove the 
water from fractions and thus avoid the aforementioned problem. This process involves 
diluting the fraction with H2O, ‘back loading’ onto PSDVB, collecting and diluting the eluent 
once more, recycling onto PSDVB, after which the column is eluted with 100% organic 
modifier. The eluent can be subsequently concentrated under reduced pressure without 
difficulty. 
Cyclic loading, to its disadvantage, is a very time consuming process, as large quantities of 
solvent are passed through the column; beginning with 200 mL of crude extract, a total of 
4.1 L of solvent is passed through the column (through both cyclic loading and back loading 
procedures). However, this issue is surpassed by the aforementioned advantages. Additionally, 
cyclic loading has been further developed for large-scale extractions (of specimens up to 1 
kg) which can be automated using an HPLC pump system. 
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Figure 1.3. Cyclic loading procedure. Adapted from West.57 
Bioassay-Guided Screening 
Secondary metabolites are created to interact with biological systems, and consequently, high 
selectivity and specificity towards a biological target are characteristics that are often 
exhibited by natural products. These characteristics have been utilised in the search for 
biologically active secondary metabolites, whereby the traditional approach to guide the 
isolation of such compounds has been via bioassay-guided screening methods.59 In this 
method, selection of a source organism is determined by whether the extract returns a 
positive result for a target biological activity. Subsequent to a positive result, purification 
processes are carried out and tracked by testing each daughter fraction against the same 
biological assay. Only biologically active fractions are further progressed through 
purification procedures. Detection by testing against a specific biological activity therefore 
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leads to the isolation and purification of compounds of potential pharmaceutical interest. In 
addition, important data about the mechanism of action is acquired at an early stage.3  
Although this screening method results in the isolation of biologically active compounds, it is 
narrowly focused on a single biological activity and can inadvertently mask minor 
biologically active compounds which pass through undetected. It is a highly sensitive 
technique utilising micromolar samples in bioassays, though it is also destructive as 
compounds are unrecoverable once biological activity is tested.55 60 
NMR-Based Screening 
Since the early 1980s, NMR spectroscopy has been used for the detection of ligand-protein 
binding to targets. However, it was in the 1990s when the technique was used to as a 
screening tool in natural products for drug discovery.61 The increase in NMR field strength, 
advances in micro-coils and cryogenic systems, and the development of capillary and micro-
probes has greatly improved the NMR sensitivity, enabling the structure elucidation of sub-
milligram quantities of natural product compounds.13 Compared with bioassay-guided 
screening, however, NMR-based screening is relatively insensitive as the sample sizes 
required for NMR experiments are still higher. On the other hand, advanced NMR techniques 
circumvent the problems often encountered with bioassay-guided fractionation. Preparation 
of NMR samples is relatively fast and experiments are comparatively quick to run. 
Additionally, NMR spectroscopy is non-destructive, meaning that samples can be used to 
easily and readily recover compounds at the end of the experiment. Successive 
chromatographic techniques for further purification can be optimised as a result of 
information obtained in regards to chemical functionality. For example, prior knowledge of 
functional groups such as acidic or basic moieties could lead to the use of ion-exchange 
media or pH buffers to provide a more efficient separation and purification of the fraction. 
Although this method of screening does not provide information on biological activity, the 
perception is that structural novelty frequently leads to interesting bioactivity.60  
1.7 Marine Natural Products, VUW Screening Methods 
Our laboratory employs an NMR-based screening method to analyse semi-purified extracts 
of marine organisms, and to guide the isolation of potentially new secondary metabolites. 
Following the extraction of a selected specimen and the subsequent cyclic loading of the 
extract onto PSDVB, the column is eluted using solutions of i) 30% Me2CO/H2O ii) 75% 
Me2CO/H2O iii) Me2CO. The 30% and 75% fractions are then backloaded onto separate 
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PSDVB columns as outlined earlier, and then each column is eluted with Me2CO. Once the 
fractions have been concentrated under reduced pressure, they are analysed by NMR 
spectroscopy. The intermediate region depicted in the mass window of Figure 1.2, would 
therefore represent the 75% fraction and should theoretically contain the majority of the 
secondary metabolites. 
NMR screening in the MNP (VUW) laboratory has been used for several years to screen semi-
purified extracts. In regards to speed of screening, economic implications, and accuracy of 
results, it has become the preferential method of screening. Initially, the 1D 1H NMR 
experiment was the screening tool used, however the level of structural data acquired was 
extremely limited.  Furthermore, signals belonging to secondary metabolites were masked at 
resonances between 0.5 and 5.5 ppm, by any primary metabolites present in the fraction.57 
The initial NMR screening protocol was further developed to include the 2D COSY and 
HSQC experiments so that resonances could be separated using the second dimension. 
Spectra obtained from these two experiments were originally used to generate a paper mask 
however manual interpretation of complex spectra was not without difficulty and prone to 
error. Due to the additional information regarding chemical group functionality provided by 
the HSQC experiment, further development of the paper mask idea, led to the generation of a 
digital HQSC mask.55, 60, 62  
The HSQC digital mask is a compilation and superimposition of HSQC spectra obtained from 
the 75% Me2CO/H2O HP20 fraction (Figure 1.4). The development of the mask involved 
electronically exporting, adding together and overlaying the HSQC spectra. Valuable 
information can be obtained by comparing peak correlations within the mask to that of the 
screen whereby common correlations appear as strong peaks and are easily identified from 
uncommon correlations which are generally weak by comparison (Figure 1.5).55, 60, 62  
Two HSQC masks were developed for New Zealand marine organisms: one for sponges and 
the other for algae.55, 60, 62 The development of the algae HSQC mask was instigated, after 
discovering an incompatibility between the algae and sponge HSQC spectra; all correlations 
in the algae HSQC screen spectra appeared unusual and thus interesting, when applied to the 
sponge HSQC mask.55 A further implication of this, is that the HSQC mask is unsuited for 
screening Tongan marine organisms and indicated that another mask was needed. Currently, 
the development of an HMBC mask is in progress which will be used for the screening of 
Tongan marine organisms.63 The HMBC experiment was selected, as it provides information 
on non-protonated functional groups which the HSQC experiment does not offer. 
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Furthermore, the multiple-bond correlations enable the determination of chemical motifs 
and the derivation of compound substructures. 
 
 (a) (b) 
Figure 1.4. (a) Digital HSQC mask (contains 160 sponges). (b) Common correlations in the 
HSQC mask. 
 
 (a) (b) 
Figure 1.5. (a) An uninteresting sponge screen. (b) An interesting screen 
1.8 Proposed Research 
Interesting antifungal activity observed for triterpene glycosides obtained from the common 
New Zealand sea cucumber, Austalostichopus mollis, prompted curiosity as to the whether 
this activity is unique to the compounds of A. mollis. In order to answer this, Tongan sea 
cucumbers will be extracted, and partially purified samples will be tested for antifungal 
activity at the School of Biological Sciences, VUW. This project will additionally investigate 
Tongan marine sponges with the aim of isolating new, potentially biologically active, 
secondary metabolites. Purification techniques will involve the use of a combination of 
reversed- and normal-phase chromatography. Partially purified extracts will be initially 
analysed by 1D and 2D NMR experiments in order to evaluate fractions of further interest, 
and the pursuit of any compounds of interest will be guided by NMR spectroscopy. NMR 
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spectroscopy and HRESIMS will be utilised in the structure elucidation of compounds and all 
new compounds will be submitted to the School of Biological Sciences, VUW, to test for 
biological activity. 
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Chapter 2 
Screening Tongan Marine Organisms 
2.1 Comparison of Antifungal Activity between Tongan Holothurians and 
 Australostichopus mollis 
Sea cucumbers are a prolific source of saponins, and in particular of triterpene glycosides. 
Triterpene glycosides are metabolites commonly found in plants and it is rare to observe 
them from animals, yet they are regularly isolated from sea cucumbers and surprisingly their 
isolation has also been reported from sponges.64 A broad biological profile has been noted for 
compounds of this type, including antifungal, cytostatic, cytotoxic, hemolytic and 
immunomodulatory activities.65  
2.1.1 Triterpene Glycosides from Australostichopus mollis 
Australostichopus mollis, the most common sea cucumber of New Zealand, was investigated 
by Greta Moraes, which led to the isolation of one known (neothyonidioside, 44) and six new 
triterpene glycosides, mollisosides A, B1, B2, C–E (45–50, respectively).40, 58, 66 A partially 
purified sample containing these compounds, exhibited antifungal activity against Rhizopus 
sp. with 90–100% inhibition at concentrations of 100 µg/mL.40 This interesting activity 
profile prompted curiosity as to whether the antifungal activity was specific to the saponins 
from A. mollis or a commonality to saponins from sea cucumbers in general. As A. mollis 
represents the most common sea cucumber found in New Zealand, such investigations aimed 
at answering this question could not proceed without access to other specimens. An 
expedition to Tonga for the collection of marine organisms provided an opportunity for other 
sea cucumbers to be investigated therefore enabling a comparison of the antifungal activity 
between saponins from Tongan sea cucumbers and A. mollis. 
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2.1.2 Tongan Holothurians  
The opportunity to collect marine organisms from Tonga allowed for the collection of a 
variety of common Tongan sea cucumbers. During a snorkel collection in late 2008, a total of 
eight different common species of holothurians were obtained, from Popua Beach, 
Tongatapu, Tonga. As these were common Tongan sea cucumbers, comparisons made against 
pictures of Tongan sea cucumbers facilitated with their identification. Four of these were 
selected for investigation.  
PTN3_13D  
PTN3_13D (Figure 2.1) has a jet black, leathery epidermis, and is tentatively identified as 
Stichopus chloronotus. A total mass of 537 g was collected, from which 70 g was extracted. 
Following HP20 cyclic loading and back loading, the 75% Me2CO/H2O fraction was obtained 
(235.6 mg) as a creamy white powder. Although the 1H NMR spectrum did not provide a 
great deal of information (Figure 2.2), the HMBC screen spectrum of the 75% Me2CO/H2O 
fraction showed correlations that were consistent with saponin-like compounds (Figure 2.3). 
 
Figure 2.1. Surface photo of PTN3_13D 
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Figure 2.2. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13D. 
 
Figure 2.3. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13D. 
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PTN3_13F 
PTN3_13F (Figure 2.4) was tentatively identified as Holothurea sp. (either H. edulus or H. 
atra). A total of 320 g was collected and 38 g was extracted. During backloading, the 75% 
Me2CO/H2O eluent began to foam as H2O was added. This observation indicated the presence 
of saponins. A total of 77.1 mg of the 75% Me2CO/H2O fraction was obtained as a white 
powder. Although, the observed foaming suggested the presence of saponins, this could not 
be ascertained with certainty from NMR data due to broad resonances in the 1H NMR 
spectrum (Figure 2.6) and very few correlations observed in the HMBC spectrum (Figure 
2.7).  
 
Figure 2.4. Surface photo of PTN3_13F 
PTN3_13G 
PTN3_13G (Figure 2.5) is tentatively identified as a Bohadschia sp. (either B. argus or B. 
simils). A total mass of 470 g was collected and 50 g was extracted. The initial dilution of the 
75% Me2CO/H2O eluent for back loading also formed a foaming solution, again indicating 
the presence of saponins. A total of 39.6 mg was obtained as a white powder from the 75% 
Me2CO/H2O fraction. In addition to the observed foaming of the eluent, the NMR data also 
suggested the presence of saponins (Figures 2.8 and 2.9). 
 
Figure 2.5. Surface photo of PTN3_13G 
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Figure 2.6. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13F. 
 
Figure 2.7. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13F. 
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Figure 2.8. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13G. 
 
Figure 2.9. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13G. 
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PTN3_13H 
PTN3_13H (Figure 2.10) possesses a dark brown exterior and has tentatively been identified 
as Bohadschia vitiensis. A mass of 70 g, out of a total 252 g was extracted. Following cyclic 
and back loading, the 75% Me2CO/H2O fraction concentrated to dryness under reduced 
pressure to afford a creamy white powder. The NMR screen spectra indicated the presence of 
saponins (Figures 2.11 and 2.12). 
 
Figure 2.10. Surface photo of PTN3_13H 
 
 
 
Figure 2.11. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction 
of PTN3_13H. 
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Figure 2.12. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN3_13H. 
2.1.3 Antifungal Activity 
Subsamples of each of the 75% Me2CO/H2O fractions were submitted to the School of 
Biological Sciences, VUW where antifungal activity against Saccharomyces cerevisiae was 
tested. The antifungal activity of the semi-purified extracts from Tongan sea cucumbers, 
appeared to be comparatively similar, to that observed for neothyonidioside (44), which has a 
minimum inhibitory concentration (MIC) of 1 M (1.1 g/mL) against S. cerevisiae.67 Close 
to 93% growth inhibition was observed for the sample from PTN3_13D at 1.1 g/mL, and 
PTN3_13H at 3.3 g/mL, and between 60–65% growth inhibition at 11g/mL§ for both 
samples obtained from PTN3_13F and PTN3_13G. Furthermore, neothyonidioside resistant 
yeast strains showed resistance to all four Tongan sea cucumber samples. These results 
suggested that the antifungal activity of the A. mollis saponins is not specific, but is rather a 
generic feature of holothurian saponins.  
The antifungal mechanism of action of neothyonidioside (44) was recently published.67 
Neothyonidioside (44) binds directly to ergosterol** in a dose-dependent manner, thereby 
disrupting the cell membrane. This study suggests that other sterol-binding antifungal 
                                                   
§ Highest administered dose. 
** Ergosterol is a sterol present in the cell membrane of fungi.  
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agents, operate in this manner.67 In view of these results, the comparable antifungal activity 
observed between the Tongan sea cucumber samples and the A. mollis triterpene glycosides is 
not surprising, since saponins are known to bind to sterols.68 It is likely that the saponins 
within the Tongan sea cucumber samples may be operating by the same mechanism within 
yeast. 
Holothurians have been extensively investigated for secondary metabolites and these are well 
represented in the literature. As our interest was purely in the comparable antifungal activity, 
Tongan sea cucumbers were not investigated any further and the focus of this project moved 
towards the investigation of new secondary metabolites from Tongan marine sponges. 
2.2 Tongan Marine Sponges 
A total of 260 sponges was collected during two collection trips to Tonga in 2008 and 2009. 
Many of these included multiple specimens of the same sponge, which have been collected 
from different geographical locations in Tonga as this can often be important in determining 
the level and type of metabolites within the organism. Sponges were collected from various 
locations in Tongatapu, ‘Eua, and the Vava’u group. Five sponges, all collected from Vava’u, 
were selected for screening and two were chosen for further analyses.  
PTN4_05C 
PTN4_05C (Figure 2.13) is a soft, biscuit-beige coloured, unidentified sponge. The exterior of 
the sponge was covered with algae. The sponge was screened (22 g) and revealed both the 
75% Me2CO/H2O and the 100% Me2CO fractions to contain one major compound, identified 
as steroidal, with olefinic signals clearly defined. No further analysis was performed. The 1H 
NMR and HMBC screen spectra are provided in Figures 2.15 and 2.16, respectively. 
 
Figure 2.13. Surface photo of PTN4_05C 
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PTN4_08B 
PTN4_08B (Figure 2.14) was a soft, beige coloured unidentified sponge. The screen of a 19 g 
sponge specimen revealed it to be the same as PTN4_05C as the spectra of both the 75% 
Me2CO/H2O and 100% Me2CO fractions were identical. Further investigations were 
discontinued. The 1H NMR screen spectrum is given in Figure 2.15. 
 
Figure 2.14. Surface photo of PTN4_08B 
 
 
 
Figure 2.15. 1H NMR (CD3OD, 600 MHz) screen spectra of the 75% Me2CO/H2O fraction of 
PTN4_05C (blue) and PTN4_08B (black). 
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Figure 2.16. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN4_05C. 
PTN4_13A 
PTN4_13A (Figure 2.17) is a white, unidentified sponge with an irregular smooth surface. 
Upon exposure to air the exterior of the sponge began to oxidise to a purple colour. 
Compared to other Tongan sponge specimens, PTN4_13A provided samples of considerably 
low mass and solubility issues were encountered. The screen NMR spectra revealed 
uninteresting resonances (Figures 2.18 and 2.19) and as such no further analysis was 
performed. 
 
Figure 2.17. Surface photo of PTN3_13A 
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Figure 2.18. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction 
of PTN4_13A 
.Figure 2.19. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN4_13A. 
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PTN4_14B 
PTN4_14B (Figure 2.20) is a hard, porous unidentified sponge with a honey-comb shape. The 
exterior is lilac in colour and highly reticulated. Underwater, the sponge appeared whitish 
blue. A small specimen (22 g) of the sponge was screened and the 75% Me2CO/H2O fraction 
was selected for further investigation due to the HMBC screen spectrum revealing a variety 
of proton resonances correlating to carbonyl and olefinic carbons (Figure 2.22). Figure 2.21 
displays the 1H NMR screen spectrum. 
 
Figure 2.20. Surface photo of PTN4_14B 
 
 
 
Figure 2.21. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction 
of PTN4_14B. 
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Figure 2.22. HMBC (CD3OD, 600 MHz) screen spectrum of the 75% Me2CO/H2O fraction of 
PTN4_14B. 
 
Continued purification methods using HP20ss, DIOL, and reversed-phase HPLC C18 (Scheme 
2.1) resulted in the isolation of three known hexahydroxylated 9,11-secosteroids: 
euryspongiols A1, A2, and B (51–53, respectively). The 1H NMR and HSQC spectra of the 
sample containing euryspongiol A1 (51) revealed the presence of another closely related 
compound comprising approximately one third of the sample. The structure of the minor 
component of the sample could not be elucidated as the signals were either too weak or 
absent in the HMBC spectrum. Euryspongiol A2 (52) was present together with euryspongiol 
B (53), with 52 being the major component of the sample by approximately 70%. The 
stereochemistry of the chiral centres present in the side chain of compounds 51–53 is 
undetermined due to the compounds existing as mixtures.  
Compounds 51–53 were originally isolated from a New Caledonian sponge Euryspongia sp., 
along with seven other euryspongiol congeners (54–60).69 The large number of 
euryspongiols reported in the literature meant that the isolation of new euryspongiol 
derivatives would be unlikely. In addition, no other fractions generated during the 
purification of 51–53 were of any interest. As a result, further studies on this sponge were 
discontinued. 
 37 
 
 
Scheme 2.1. Isolation procedure for compounds 51–53 from PTN4_14B. 
 
51 R = OH R1 = H R2 =  56 R = OH R1 = H R2 =  
52 R = OH R1 = H R2 =  57 R = H R1 = OH R2 =  
53 R = H R1 = OH R2 =  58 R = H R1 = OH R2 =  
54 R = OH R1 = H R2 =  59 R = H R1 = OH R2 =  
55 R = OH R1 = H R2 =  60 R = H R1 = OH R2 =  
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PTN4-10B and PTN4_08E 
PTN4_10B and PTN4_08E (identical sponge) (Figure 3.1) was firm but springy with a dark 
brown exterior, a green-brown interior and an odour slightly reminiscent of garlic. The 
screen of the 100% Me2CO fraction showed interesting signals in the aromatic region of the 
spectrum and was selected for further investigation accordingly. The study of this sponge and 
isolated compounds will be discussed in Chapter 3. 
NMR spectroscopy has been used effectively to identify sponge extracts with interesting 
chemical characteristics and those with less interesting chemical profiles, early in the 
investigation. Despite this, it is important to note that the use of the HMBC mask as a 
screening tool in the future, will greatly increase the ease and efficiency by which extracts 
can be evaluated in order to determine sponges containing interesting secondary metabolites. 
PTN4_05C and PTN4_08B were initially considered as different sponges due to the fouling 
algae accumulated on the surface of PTN4_05C. Through NMR screening, these two sponges 
were discovered to be identical very early on in the study. This may not have been recognised 
as early in the investigation if a bioassay guided screening protocol had been utilised. Two 
sponges were selected for further analysis due to interesting resonances in the NMR screen 
spectra, which resulted in the isolation of a mixture of known and new compounds. 
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Chapter 3 
New Fascaplysin Congeners from a Sponge of the Order 
Dictyoceratida 
During the course of our groups screening of Tongan sponges, a dark brown sponge, PTN4_10B 
(Figure 3.1) was discovered to contain interesting aromatic resonances in the 75% Me2CO/H2O 
HP20 fraction. Further investigation of the sponge was postponed while other samples were 
investigated by members of the Marine Chemistry group. Interest in the aromatic resonances 
instigated a re-examination of the sponge, which ultimately led to the isolation of two known 
compounds and four new fascaplysin derivatives.  
The digestion of a small sponge specimen, in concentrated HNO3 and in NaOCl established the 
sponge to be devoid of silicaceous and calcitic spicules. A search through the literature for 
related compounds to those isolated from PTN4_10B, revealed that the host sponges belonged to 
the family Thorectidae, order Dictyoceratida. Taking these into account, in addition to the 
texture of the sponge, PTN4_10B has tentatively been assigned to the order Dictyoceratida and 
may possibly belong to the family, Thorectidae. 
3.1 Order Dictyoceratida 
The order Dictyoceratida encompasses four families of sponges, Thorectidae, Dysideidae, 
Spongiidae, and Irciniidae and 36 described genera, although several more are yet to be 
described and classed into this order. The lack of mineral (silicaeous) spicules within 
Dictyoceratid sponges often complicates the task of taxonomic identification. General 
characteristics of Dictyoceratid sponges include a tough and compressible texture which is 
usually conulose (the surface is manifested with conules or elevated cones). The level of 
flexibility of the sponge can vary depending on the density of the fibre skeleton, or whether 
debris is incorporated within the sponge matrix. Marked differences between the exterior and 
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interior pigmentation are often observed, with the outer surface usually being very dark in 
colour and the inner much lighter by comparison. A diverse range of terpenoids have been 
found from sponges of this order and to account for them all is beyond the scope of this report.30 
 
Figure 3.1. Surface photo of PTN4_10B 
3.2 The Isolation of Known and New Compounds 
PTN4_10B (Figure 3.1) was collected by SCUBA from Fakafotula  (a small island near the Port of 
Refuge), Vava’u, Tonga. A total of 92 g was extracted in MeOH twice overnight, and the extracts 
were subsequently cyclic loaded onto pre-equilibrated reversed-phase PSDVB sorbent. Upon 
completion of cyclic loading, the beads were consecutively batch eluted with 30% Me2CO/H2O, 
75% Me2CO/H2O, and 100% Me2CO. Although the 75% fraction is generally the fraction of 
interest in regards to secondary metabolites (Figure 1.2), the 1H NMR screen spectrum of the 
100% fraction revealed interesting aromatic resonances between H 7.50–8.75 (Figure 3.2). For 
this reason, the 100% Me2CO fraction was chosen for further investigations, in pursuit of the 
compound responsible for the aromatic resonances.  
 
Figure 3.2. 1H NMR (CD3OD, 600 MHz) screen spectrum of the 100% Me2CO fraction from the 
sponge PTN4_10B.  
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DIOL flash column chromatography was employed as the next step for purification which 
afforded the known compounds ambliol B (61) from 20% DCM/pet. ether and luffariellolide 
(55) from the 5% EtOAc/DCM fraction (Scheme 3.1). Faulkner and Walker first reported the 
isolation of the diterpenoid ambliol B (61) from Dyisdea amblia in 1980.70 Luffariellolide (62), is 
a sesterterpene initially isolated from the Palauan sponge Luffariella sp. in 1987.71 Shortly 
thereafter, 62 was independently isolated by a separate research group from a Fijian sponge 
Fascaplysinopsis sp.72 Both Dysidea and Luffariella belong to the order Dictyoceratida.30  
  
 
New Compounds 
In addition to the isolation of the known compounds 61 and 62, four new fascaplysin 
derivatives were isolated. A fraction eluting from the DIOL column in 10% H2O/MeOH was 
determined by NMR spectroscopy to contain 7-bromoreticulatine (63). The 1H NMR spectrum of 
the 50% MeOH/DCM DIOL fraction showed more of the aromatic resonances that were of 
interest and was therefore purified further. The fraction was re-chromatographed on DIOL 
(flash) and the fractions analysed by NMR spectroscopy, which showed that the aromatic 
resonances were confined to the 20% DCM/MeOH fraction. Attempts to purify the sample on 
reversed-phase C18 HPLC using MeCN and H2O was unsuccessful due to streaking and altering 
the conditions to a lower ratio of MeCN/H2O or to a 0.01% acidified solution (formic acid) 
proved ineffective. Consequently, the sample was chromatographed on normal-phase HPLC 
(DIOL, IPA/n-hexane) to give three fractions. The first two fractions contained the pure 
compounds 10-bromo-6,7-dimethoxyhomofascaplysin C (64) and D (65), while the last 
contained, an impure sample of a related compound. Purification of this sample using reversed-
phase C18 HPLC was re-attempted using more acidic conditions (30% MeCN/0.5 M HCOOH(aq)) 
yielded 10-bromohomofascaplysin A (66). The isolation procedure is outlined in Scheme 3.1. 
61 62 
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Scheme 3.1. Isolation procedure for compounds 61–66 from PTN4_10B 
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3.2.1 10-Bromohomofascaplysin A 
10-Bromohomofascaplysin A (66) was isolated as a yellow solid. The compound was isolated 
in conjunction with a persistent long chain alkyl moiety, identified via resonances in the 1H 
and 13C NMR spectra (H 0.84–0.87, 1.25; C 29.7 and 14.1) and another minor impurity 
which displayed resonances between H 1.0-3.5. Despite many attempts, using a variety of 
different chromatographic methods, these impurities remained inseparable. Not surprisingly, 
an examination of literature supplemental data demonstrates this to be a commonly 
encountered feature observed among the fascaplysins.73  
Positive ion mode HRESIMS revealed characteristic ion clusters ([M]+ : [M + 2]+; 1 : 1) 
indicative of the presence of bromine and consistent with a molecular formula 
C21H16N2O2Br+ (m/z 407.0395, [M]+,  0.0 ppm). With an apparent double bond equivalent 
of 14.5 and the observation of an [M]+ in electrospray ionisation mode, the compound was 
determined to be a natively charged species. The 1H NMR spectrum indicated only 15 of the 
16 protons (one of which was observed as a broad singlet at H 13.73 attributed to a NH 
proton). Lack of observation of the last proton in the 1H NMR spectrum could be accounted 
for as another exchangeable; the presence of two exchangeable protons within the molecule 
is substantiated by the absence of two protonated signals from the HSQC. Inspection of the 
13C NMR spectrum showed 20 distinct carbon resonances accredited to the compound, while 
the final carbon unaccounted for was determined from observed three-bond correlations in 
the HMBC spectrum.  
Analysis of the multiplicity-edited HSQC spectrum provided information on the direct 
connectivity of 14 protons to their corresponding carbons, giving nine aromatic methines, 
one highly deshielded diastereotopic methylene pair, and one methyl singlet. The remaining 
ten non-protonated carbon resonances were attributed to a ketone carbon (C 204.5), eight 
substituted aromatic carbons (C 145.7, 143.7, 140.4, 136.6, 134.0, 130.8, 127.5, 118.3) and 
one quaternary oxygenated carbon (C 78.0).  
Examination of the COSY and HMBC data, in addition to the multiplicities of the aromatic 
protons established the connectivity from C-1a through to C-4a. COSY correlations were 
observed between the aromatic methine protons, CH-1 (H 7.65, C 124.7) and CH-2 
(H 7.52, C 130.6), CH-3 (H 7.56, C 130.7) and CH-4 (H 7.62, C 113.2) and between 
CH-2 and CH-3. Prevalent correlations observed within aromatic systems in an HMBC 
spectrum are three-bond couplings, and when two- and four-bond couplings are present 
their crosspeak intensities are typically weak by comparison.74 With this in mind, HMBC data 
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confirmed the connectivity ascertained using the COSY experiment and established the 
positions of the non-protonated aromatic carbons, to give a 1,2-disubstituted aromatic ring. 
Correlations in the HMBC spectrum were observed from H-4 to C-2 and to the non-
protonated carbon C 1a (C 136.6). H-1 correlated to both C-3 and the non-protonated 
aromatic carbon, C 4a (C 140.4). One additional weak HMBC correlation was observed from 
H-1 to the quaternary carbon C-13 (C 78.0), deduced to be the substituent at C-1a. Three-
bond correlations were also evident from H-2 to C-4 and C-1a, and from H-3 to C-1 and 
C-4a. The HMBC and COSY correlations are outlined in Figure 3.3.  
 
Figure 3.3. COSY and HMBC correlations establishing the connectivity between C-4a and 
C-13 in 10-bromohomofascaplysin A (66). 
A long-range COSY correlation was observed between the methyl singlet, CH3-16 (H 1.89, 
C 30.1) and one of the two diastereotopic methylene doublet protons, CH2-14 (Ha 3.92, 
Hb 4.66, C 51.3), indicating a close proximity between these protons. As expected, both 
protons on CH2-14 coupled to one another. HMBC correlations from H3-16 included strong 
correlations to C-14 and to C-15 (C 204.5) and a weak correlation to C-13, suggesting a 
connection between this substructure and that outlined in Figure 3.3. Confirmation of the 
link between the two substructures was provided by HMBC correlations observed from H2-14 
to C-13, and C-1a. Both of the protons of CH2-14 correlated to C-15 and C-16. One further 
correlation, from H2-14 to C-12b (C 143.7), indicated the placement of a non-protonated 
aromatic carbon adjacent to C-13 (Figure 3.4).  
 
Figure 3.4. COSY and HMBC correlations establishing the connectivity between C-13 and 
C-16 in 10-bromohomofascaplysin A (66). 
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The deshielded aromatic methine protons, CH-8 (H 7.81, C 124.0) and CH-9 (H 7.17, 
C 125.9), showed COSY correlations to each other. CH-9 also displayed a long range COSY 
correlation to the relatively deshielded singlet aromatic proton, CH-11 (H 8.04, C 116.5). 
These correlations suggested a 1,2,4-trisubstituted aromatic ring. Support for this 
arrangement was obtained through HMBC correlations. Both H-9 and H-11 displayed a 
correlation to the non-protonated aromatic carbon C-7b and a reciprocal correlation to each 
other. A third weak correlation was observed from H-11 to the non-protonated aromatic 
carbon C-10 (C 127.5). The aromatic methine proton H-8, only correlated to non-
protonated carbons; two strong HMBC correlations were observed to C-10, and C-11a 
(C 145.7) and a weak correlation to C-7a (C 134.0) was displayed. As this weak correlation 
did not correspond to a two-bond coupling, it was considered that the strong correlations 
were three-bond couplings within the aromatic ring, while the weak correlation was a 
three-bond coupling to the substituent on C-7b. Although the positions of C-10 and C-11a 
within the aromatic ring were certainly meta- in relation to CH-8, they remained ambiguous 
at this stage as they could have been on either side of the ring. They are placed correctly in 
Figure 3.5, however, it should be noted that this was not deduced until a later stage of the 
structure elucidation. Figure 3.5 illustrates the COSY and HMBC correlations.  
 
Figure 3.5. COSY and HMBC correlations establishing the connectivity between C-7b and 
C-11a in 10-bromohomofascaplysin A (66). 
A third aromatic ring was determined through analysis of the COSY and HMBC data. COSY 
data of CH-6 (H 8.49, C 122.2) and CH-7 (H 8.29, C 117.0) showed the two aromatic 
protons coupling to each other but not to any other protons. HMBC correlations were 
observed from H-6 to C-7 and from H-7 to C-6 and all other correlations from both protons 
were to non-protonated aromatic carbons, suggesting a 1,2,3,4-tetrasubstituted aromatic 
ring. Further HMBC correlations include H-7 to C-7b and C-12a (C 130.8), while three 
correlations were observed from H-6; one to C-4a, another to C-7a (C 134.0) and the last to 
C-12b. Specifically, these correlations to C-4a, C-7b, and to C-12b indicated an 
interconnection to both substructures illustrated in Figures 3.4 and 3.5 and further suggested 
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the existence of a five membered ring system between this substructure, and the one outlined 
in Figure 3.4.  
Of all the aromatic protons, H-6 and H-7 were the most highly deshielded and their 3JHH 
coupling constants were considerably lower by comparison at 5.8 and 6.2 Hz, respectively. 
Furthermore, the 1JCH of CH-6 (188 Hz) was significantly larger than all others. Based on this 
evidence, it was clear that these two aromatic protons were experiencing a disparate 
chemical environment to the other aromatic protons. With 14.5 double bond equivalents 
indicating the compound to be a positively charged species, a pyridinium cation substructure 
was proposed, with H-6 adjacent to the nitrogen in view of the fact that it appeared the most 
deshielded. As the HMBC data suggested a connection between this substructure and those 
illustrated in Figures 3.4 and 3.5, it was postulated that the three together must form a 
pentacyclic aromatic system, which could be validated if the substructure from Figure 3.5 
contained an indole functionality. The proposed structure accounts for all double bond 
equivalents, carbons, nitrogens, oxygens and 15 of the 16 hydrogens. With only one 
hydrogen and the bromine left to assign, this implied that the oxygen connected to C-13 was 
a hydroxyl functionality and the bromine was substituted at C-10. This highly aromatic 
pentacyclic ring system is not without precedence in marine natural products, belonging to 
the marine natural products class of compounds known as the fascaplysins.73a, 75  
Reassessment of the HMBC correlations from H-6, H-7 and H-8 in addition to NOESY data 
confirmed the validity of the proposed structure. Valuable information was obtained from the 
NOESY experiment, with the most significant observations including correlations between 
H-6 and H-4, H2-14 and H-1, and H-7 and H-8 (Figure 3.6). C-10 and C-11a were 
ultimately assigned to their positions based on the chemical shifts of related compounds 
reported in the literature.73, 75 The structure of 10-bromohomofascaplysin A (66) is therefore 
provided in Figure 3.6 and is accompanied with NMR data in Tables 3.1 (CDCl3) and 3.2 
(CD3OD). 
 
Figure 3.6. Key COSY, HMBC, and NOESY correlations between the substructures providing 
the structure of 10-bromohomofascaplysin A (66). 
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Table 3.1. 13C (150 MHz) and 1H (600 MHz) NMR data (CDCl3) for 10-Bromohomofascaplysin A (66). 
 
 
  
 
  13C   1H   HMBC 
 
Pos ppm) Mult J 
(Hz) 
  (ppm) mult J (Hz)   COSY (1H to 13C) 
 
1a 136.6 C         
 1 124.7 CH 168  7.65 d 7.3  2 3, 4a, 13 
 2 130.6 CH 169  7.52 t 7.4  1, 3 1a, 4 
 3 130.7 CH 169  7.56 t 7.4  2, 4 1, 4a 
 4 113.2 CH 168  7.62 d 7.7  3 1a, 2 
 4a 140.4 C         
 6 122.1 CH 188  8.49 d 5.8  7 4a, 7, 7a, 12b  
 7 117.0 CH 173  8.29 d 6.2  6 6, 7b, 12a 
 7a 134.0 C         
 7b 118.3 C         
       8 124.0 CH 166  7.81 d 8.7  9 7a,10, 11a 
       9 125.9 CH 171  7.17 d 8.5  8, 11* 7b, 11 
       10 127.5 C         
       11 116.5 CH 176  8.04 s   9* 7b, 9, 10 
       11a 145.7 C         
       12a 130.8 C         
       12b 143.7 C         
       13 78.0 C         
       14a 51.3 CH2 127  3.92 d 18.7  14b, 16* 1a,12b, 13, 15, 16 
       14b 127  4.66 d 18.7  14a 1a, 13, 15 
       15 204.5 C         
       16 30.1 CH3 128  1.98 s   14b* 14, 15 
       NH        13.73 br s         
 
*   Long-range coupling 
     
 
         
                
 
66 
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Table 3.2. 13C (150 MHz) and 1H (600 MHz) NMR data (CD3OD) for 10-Bromohomofascaplysin A (66). 
 
   13C   1H   HMBC   
 Pos ppm) mult   (ppm) mult J (Hz) COSY (1H to 13C) NOESY 
 1a 137.2 C         1 124.4 CH  7.89 d 7.6 2 3, 4a, 13 2, 14a, 14b  2 130.6 CH  7.69 t 7.3 1, 3 1a, 4, 4a* 1, 3  3 130.9 CH  7.75 t 7.3 2, 4 1, 4a 2, 4  4 113.9 CH  8.26 d 7.9 3 1a, 2 3, 6  4a 141.5 C         6 124 CH  9.35 d 3.9 7 ** 4, 7  7 117.3 CH  8.82 d 3.9 6 ** 6, 8 
   
 7a 134.8 C        
   7b 118.9 C        
     8 124.5 CH  8.37 d 8.6 9 10, 11a 7, 9 
     9 125.8 CH  7.63 d 8.5 8, 11* 7b, 10, 11 8 
     10 126.7 C        
     11 115.7 CH  8.02 s  9* 7b, 9, 10, 11a  
     11a 145.8 C        
     12a 131.1 C        
     12b 143.8 C        
     13 77.8 C        
     14a 50.1 CH2  4.22 d 18.8 14b 1a, 13, 15 1, 16 
     14b  4.17 d 18.8 14a, 16* 1a, 12b, 13, 15 1, 16 
     15 204.5 C        
     16 28.7 CH3   1.98 s   14b* 13, 14, 15 14a, 14b 
  *  Long-range coupling            
 
** Not observed  
          
 
  
          
66 
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3.2.2 10-Bromo-6,7-dimethoxyhomofascaplysin D 
10-Bromo-6,7-dimethoxyhomofascaplysin D (65) was isolated as a yellow solid. 
Characteristic quasi-molecular ion clusters ([M - H]- : [M + 2 - H]-; 1 : 1) by negative ion 
mode HRESIMS again indicated the presence of bromine, which was confirmed with the 
molecular formula C23H20N2O3Br (m/z 451.0654, [M - H ]-,  -0.7 ppm). This molecular 
formula requires 14.5 double bond equivalents and thus the molecular formula 
C23H21N2O3Br gives rise to 14 degrees of unsaturation. Consequent to the low mass of 
10-bromo-6,7-dimethoxyhomofascaplysin D isolated (128 µg), only a few signals were 
observed in the 13C NMR spectrum and therefore the HSQC and HMBC experiments were 
depended upon for establishing the chemical shifts of the carbon resonances. The 1H NMR 
spectrum acquired in CDCl3 revealed 12 distinct resonances which accounted for 20 of the 
21 protons. The absence of one proton suggested the presence of an exchangeable. Evidence 
for this was provided by the presence of a singlet in the 1H NMR spectrum at H 11.69 
(d6-DMSO), which did not correspond to any carbon in the HSQC experiment.  
Prominent dissimilarities between the 1H NMR spectra of 10-bromohomofascaplysin A (66) 
and 10-bromo-6,7-dimethoxyhomofascaplysin D (65) were noted, including the lack of the 
highly deshielded aromatic proton resonances above H 8.00, and the emergence of four new 
proton resonances (H 5.85, 4.98, 3.36, 3.29). Also, the methyl ketone proton singlet had 
shifted to a greater chemical shift, H 2.36. The multiplicity-edited HSQC spectrum revealed 
seven aromatic methines, two oxymethines, two oxymethyls, one diastereotopic methylene 
pair, and one methyl singlet. This signified that the other ten carbons were non-protonated. 
Structure elucidation was carried out in a similar fashion to that of 
10-bromohomofascaplysin A (66), beginning with the aromatic proton resonances. COSY 
correlations were observed from CH-1 (H 7.68, C 118.2) to CH-2 (H 7.23, C 120.9), and 
CH-3 (H 7.32, C 123.6) to CH-4 (H 7.54, C 109.6) and between CH-2 and CH-3. The 
HMBC data showed correlations from H-1 to C-3 , H-3 to C-1 and a mutual correlation 
from both protons to the non-protonated aromatic carbon C-4a (C 138.6). Further 
correlations in the HMBC spectrum were observed from H-2 to C-4, H-4 to C-2 and from 
both protons to the non-protonated aromatic carbon C-1a (C 128.3). These correlations 
implied a 1,2-disubstituted aromatic ring. One weak HMBC correlation was displayed from 
H-1 to the non-protonated olefinic carbon C-13 (C 104.0). All correlations can be seen in 
Figure 3.7. 
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Figure 3.7. COSY and HMBC correlations establishing the connectivity between C-4a and 
C-13 in 10-bromo-6,7-dimethoxyhomofascaplysin D (65). 
The diastereotopic methylene protons CH2-14 (Ha 3.79, Hb 4.22, C 39.7) showed COSY 
correlations to each other and a long range coupling to the methyl singlet protons CH3-16 
(H 2.36, C 29.4). HMBC correlations were observed from H2-14 to C-16. Both sets of 
protons also showed a mutual correlation to C-15 (C 209.1). Additionally, the H2-14 
protons correlated to C-13, C-1a, and C-12b (C 126.4). These correlations provided 
evidence of a connection between this substructure and that outlined in Figure 3.7 to give the 
substructure outlined below (Figure 3.8). 
 
Figure 3.8. COSY and HMBC correlations establishing the connectivity between C-13 and 
C-16 in 10-bromo-6,7-dimethoxyhomofascaplysin D (65). 
COSY correlations were observed between CH-8 (H 7.54, C 119.4) and CH-9 (H 7.28, 
C 124.1) and a long range correlation was also observed between CH-9 and CH-11 
(H 7.73, C 115.1). Analysis of the HMBC spectrum revealed correlations from H-8 to two 
non-protonated aromatic carbons C-10 (C 116.0) and C-11a (C 138.0), from H-9 to C-7b 
(C 126.8) and C-11, and from H-11 to C-7b, C-9, and C-10. The COSY and HMBC data 
indicated the substructure to be a 1,2,4-trisubstituted ring. Taking into consideration the 
structure of 10-bromohomofascaplysin A (66), the position of the bromine was assigned 
accordingly to this aromatic ring and deduced to be attached to C-10, as this carbon was 
relatively more shielded than C-11a (Figure 3.9).  
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Figure 3.9. COSY and HMBC correlations establishing the connectivity between C-7b and 
C-11a in 10-bromo-6,7-dimethoxyhomofascaplysin D (65). 
In the next substructure, the highly deshielded oxymethines CH-6 (H 5.84, C 83.9) and 
CH-7 (H 4.98, C 72.4) displayed mutual COSY correlations to each other. HMBC 
correlations were observed from H-6 to C-7 and to the non-protonated carbons C-7a 
(C 107.1) and C-12b, and to the methyl singlet, C-17 (H 3.29, C 56.4), and from H-7 to 
non-protonated carbons C-6 (C 83.9), and C-12a (C 129.0), and the methyl singlet C-18 
(H  3.36, C 56.3). The observed correlation from H-6 to C-12b indicated a connection to the 
substructure outlined in Figure 3.8. Furthermore, the correlations from H-6 to C-7a and 
from H-7 to C-12a suggested the presence of a double bond within this substructure. 
Accounting for all the rings and double bonds thus far, gives a total of 11 of the 14 double 
bond equivalents. All carbons indicated by the molecular formula were accounted for and 
thus the remaining degrees of unsaturation could be explained by the addition of three other 
rings therefore suggesting again a pentacyclic system as observed in 66. The index of 
hydrogen deficiency did not indicate the compound to be a charged species and so it was 
inferred that a tertiary nitrogen was in place adjacent to CH-6, giving rise to a hemiaminal 
ether moiety (Figure 3.10). There is no literature precedent for this functionality among 
naturally-derived members of the fascaplysin family. Of particular significance towards the 
suspected functionality was the proton chemical shift of the oxymethine, CH-6 in addition to 
the one-bond coupling constant (1JCH) of 158 Hz, which were both unusually high for a 
typical oxymethine.76 Acetal functionality was considered but quickly ruled out due to two 
reasons: firstly, the 13C chemical shift of CH-6 was too low for an acetal carbon as they 
typically resonate closer to ~C 10077 and secondly, all three oxygens were already assigned 
to the two methoxy groups and the ketone. Another postulated moiety was an epoxide, but 
again the methoxy groups in addition to the chemical shift of H-6 eliminated this possibility. 
Validation of the hemiaminal ether functionality is discussed further in section 3.4.  
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Figure 3.10. COSY and HMBC correlations establishing the connectivity between C-6 and 
C-12 in 10-bromo-6,7-dimethoxyhomofascaplysin D (65). 
In accordance with the molecular formula, one nitrogen and one hydrogen were the final 
two atoms to assign within the structure. As previously mentioned, the structure was deduced 
to contain a pentacyclic system, determined from the number of double bond equivalents, 
signifying that the substructures in Figures 3.9 and 3.10 were interconnected via a ring 
system containing the nitrogen. In the HMBC spectrum, the exchangeable nitrogen proton 
(H 11.69, d6-DMSO) was found to correlate to C-7a, C-7b and C-12a confirming the 
placement of the nitrogen, and the connectivity between the two substructures. NOESY 
correlations reinforced the elucidated structure, with the most pertinent being between H-4 
and H-6, H-7 and H-8, and H-1 and H-14a (Figure 3.12). 
One final analysis remained: the relative stereochemistry between H-6 and H-7. Usually NOE 
or NOESY enhancement experiments provide useful information in regards to establishing 
relative stereochemistry. However, these experiments were unaccommodating for this 
particular task due to the high level of sp2 centres within the molecule. Instead, analysis of 
the 3-bond proton-proton (3JHH) coupling constants and molecular mechanics calculations 
were relied on to tentatively assign the relative stereochemistry.  
Interpretation of the 3JHH coupling constants of 1.8 and 1.6 Hz, for H-6 and H-7, respectively, 
indicated an approximate dihedral angle of either 60o or 120o between the vicinal protons. 
An eclipsed conformation, with a proton-proton dihedral angle of 120o, was discounted due 
to considerable torsional and angle strain expected to be imposed across N-5 through to 
C-7a. An equilibrium geometry optimisation using the Hartree Fock 3-21G* calculation, was 
performed on the cis- (R*,R*) and trans- (R*,S*) configurations in order to gain calculated 
dihedral angles (Figure 3.11). The calculation indicated the cis- configuration as having a 
dihedral angle closest to 60o and accordingly, cis- stereochemistry is tentatively assigned to 
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65. The structure of 65 is given in Figure 3.12, with NMR data presented in Tables 3.3 
(CDCl3) and 3.4 (d6-DMSO). 
 
Figure 3.11. Calculated dihedral angle between the vicinal protons of possible configurations 
as deduced from the 3JHH coupling constants for H-6 and H-7. 
 
Figure 3.12. Key HMBC and NOESY correlations establishing the structure of 10-bromo-6,7-
dimethoxyhomofascaplysin D (65).
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Table 3.3. 13C (150 MHz) and 1H (600 MHz) NMR data (CDCl3) for 10-Bromo-6,7-dimethoxyhomofascaplysin D (65). 
 
 
 
 
 
 
  13C   1H   HMBC   
  
Pos ppm) mult J (Hz)   ppm) mult J (Hz) COSY (1H to 13C) NOESY 
  
1a 128.3 C         
  
1 118.2 CH 158  7.68 d 7.9 2 3, 4a, 13 2, 14a, 16 
  
2 120.9 CH 160  7.23 t 7.1 1, 3 1a, 4 1, 3 
  
3 123.6 CH 162  7.32 t 7.1 2, 4 1, 4a 2, 4 
  
4 109.6 CH 163  7.54** d 7.3 3 1a, 2 6, 17 
  
4a 138.6 C         
  
6 83.9 CH 159  5.84 d 1.8 7 7, 7a, 12b 17 4, 7, 17 
  
7 72.4 CH 149  4.98 d 1.6 6 6, 7a, 12a, 18 6, 8, 18 
  
7a 107.1 C         
 
  
 
 
7b 126.8 C         
 
  
  
8 119.4 CH 165  7.54** d 7.3 9 10, 11a 7, 9, 18 
 
  
  
9 124.1 CH 169  7.28 dd 8.5, 1.6 8, 11* 7b, 11 8 
 
  
  
10 116.0 C         
 
  
  
11 115.1 CH 166  7.73 d 1.4 9* 7b, 9, 10  
 
  
  
11a 138.0 C         
 
  
  
12a 129.0 C         
 
  
  
12b 126.4 C         
 
  
  
13 104.0 C         
 
  
  
14a 39.7 CH2 129  4.22 d 12.9 14b, 16* 1a, 12b, 13, 15 1, 14b, 16 
 
  
  
14b 131  3.79 d 12.9 14a, 16* 1a, 12b, 13, 15, 16 14a, 16 
 
  
  
15 209.1 C         
 
  
  
16 29.4 CH3 125  2.36 s  14a*, 14b* 14a, 14b, 15 1, 14a, 14b 
 
  
  
17 56.4 CH3 143 
 
3.29 s 
  
6 6, 4 
 
  
  
18 56.3 CH3 140 
 
3.36 s 
  
7 7, 8 
 
  *   Long-range coupling  
 
 
 
 
  
    
 
  ** Assignment interchangeable  
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Table 3.4. 13C (150 MHz) and 1H (600 MHz) NMR data (d6-DMSO) for 10-Bromo-6,7-dimethoxyhomofascaplysin D (65). 
 
 
 
 
  13C   1H   HMBC 
 
 
 
 
Pos ppm) mult J (Hz)   ppm) mult J (Hz) COSY (1H to 13C) 
 
  
1a 128.9 C        
 
  
1 119.5 CH 162  7.47 d 7.1 2 3, 4a 
 
  
2 120.4 CH 162  7.08 t 7.4 1, 3 1a, 4 
 
  
3 123.5 CH 163.  7.24* t 7.6 2, 4 1, 4a 
 
  
4 110.2 CH 162  7.80 d 8.4 3 1a, 2 
 
  
4a 138.9 C        
 
  
6 82.9 CH 162  6.05 d 2 7 7, 7a, 12b 17 
 
  
7 71.6 CH 149  4.99 d 1.8 6 6, 7a, 12a, 18 
 
  
7a 107.9 C        
 
  
7b 126.9 C        
 
  
8 120.3 CH 165  7.71 d 8.4 9 10, 11a 
 
   
  
 
9 123.5 CH 163  7.24* dd 8.3, 1.8 8 7b, 11 
 
    
10 114.9 C        
 
    
11 114.7 CH 166  7.66 d 1.5  7b, 9, 10 
 
    
11a 138.6 C        
 
    
12a 129.3 C        
 
    
12b 125.4 C        
 
    
13 106.7 C        
 
    
14a 39.4 CH2 125  4.21 d 17.4 14b 1a, 12b, 13, 15 
 
    
14b 127  4.36 d 17.4 14a 1a, 12b, 13, 15 
 
    
15 206.2 C        
 
    
16 30.0 CH3 126  2.36 s   14a, 14b, 15 
 
    
17 55.7 CH3 141 
 
3.29 s 
  
6 
 
    
18 55.9 CH3 142 
 
3.36 s 
  
7 
 
    
NH        11.69 s     7a, 7b, 12a 
 
  
* Assignment interchangeable
   
 
       
       
 
      
65 
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3.2.3 10-Bromo-6,7-dimethoxyhomofascaplysin C 
Negative ion mode HRESIMS of the bright yellow solid, 10-bromo-6,7-
dimethoxyhomofascaplysin C (64), gave rise to a quasi-molecular ion with a molecular 
formula C21H16N2O3Br (m/z 423.0348, [M - H]-, 0.9 ppm). Requiring 14.5 double bond 
equivalents, this indicated that the molecular formula C21H17N2O3Br possesses 14 degrees of 
unsaturation. The presence of bromine was evidenced by the observation of a prominent 
[M + 2 - H]- peak of near equal abundance to the parent quasi-molecular ion peak. The 
molecular formula differed to that observed for 10-bromo-6,7-dimethoxyhomofascaplysin 
D (65) by the loss of C2H4 and consequently suggested that the two were conceivably similar 
in structure. 1H NMR spectroscopy revealed the presence of 13 proton resonances accounting 
for all 17 protons. Data acquired from the 13C NMR experiment was unfortunately 
inadequate, showing very few of the carbon resonances due to an insufficient mass (83 g). 
Therefore, the HSQC and HMBC experiments were depended upon to provide information 
about carbon chemical shifts. 
In contrast to 65, the 1H NMR spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin C (64) 
appeared to show less resonances in the aromatic region, however, analysis of the HSQC 
spectrum showed that a few proton resonances were overlapping. The presence of two 
deshielded oxymethines and two oxymethyls, similar to those observed in 65 were detected. 
Absent from the 1H NMR were the diastereotopic methylene pair, and methyl singlet while 
the emergence of a considerably deshielded proton singlet was observed at H 10.39. One 
further resonance observed at H 11.78 was attributed to an exchangeable proton which was 
confirmed by analysis of the HSQC spectrum whereby a correlation to this resonance was 
absent.  
In addition to the two deshielded oxymethines and oxymethyls, the HSQC spectrum further 
revealed 7 aromatic methines, and an aldehyde whose carbon chemical shift appeared 
relatively shielded (C 185.1) indicating the presence of an ,-unsaturated aldehyde. The 
disappearance of the diastereotopic methylene pair and methyl ketone and occurrence of the 
aldehyde is consistent with the loss of C2H4 from the molecular formula of 65, suggesting 
that C-13 in 65, is substituted by an aldehyde in compound 64.  
Beginning with the aromatic resonances, structure elucidation was carried out similarly to 
that used for the previous two structures. Again, the presence of a 1,2-disubstituted and a 
1,2,4-trisubstituted benzene ring was established through interpretation of HMBC and COSY 
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data, and since the elucidation of these substructures has been explained in sections 3.2.1 
and 3.2.2, it is unnecessary to elaborate further on the observed correlations. Like 65, a 
hemiaminal ether functionality was also suggested in 64, through the comparatively similar 
chemical shifts of oxymethines, CH-6 (H 5.94, C 85.0) and CH-7 (H 5.06, C 71.7), and the 
CH-6 1JCH coupling constant (165 Hz). COSY correlations between H-6 and H-7 established 
a vicinal relationship between these two protons, while HMBC correlations from both 
protons to their respective oxymethyl carbons and to the non-protonated olefinic carbons 
C-7a (C 109.7), C-12a (C 126.9), C-12b (C 133.2) confirmed the identical nature of the 
carbon skeleton of the cyclic portion, to that of 65. The only difference remaining between 
the two molecules was indeed the replacement of the ketone by the aldehyde. This was 
established through the HMBC correlations from the aldehyde, H-14 (H 10.39) to C-13 
(C 112.3) and C-12b and further substantiated by an observed NOESY correlation from 
H-1 (H 8.01) to H-14 (Figure 3.13).  
The relative stereochemistry of H-6 and H-7 was considered to be analogous to that of 65 on 
account of the congruent 3JHH coupling constants. For consistency, an equilibrium geometry 
optimisation using the Hartree Fock 3-21G* calculation was performed and again the cis- 
(R*,R*) configuration was found with the closest dihedral angle to 60o. Therefore, cis- 
stereochemistry is tentatively assigned and the structure of 
10-bromo-6,7-dimethoxyhomofascaplysin C (64) is given in Figure 3.13, with NMR data 
presented in Table 3.5.  
 
Figure 3.13. COSY, HMBC, and key NOESY correlations establishing the structure of 
10-bromo-6,7-dimethoxyhomofascaplysin C (64).  
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Table 3.5. 13C (150 MHz) and 1H (600 MHz) NMR data (CDCl3) for 10-Bromo-6,7-dimethoxyhomofascaplysin C (64).  
 
 
 
  13C     1H     HMBC   
 
 
 
Pos ppm) mult J (Hz)   ppm) mult J (Hz)   COSY (1H to 13C) NOESY 
  
1a 128.0 
          
  
1 118.2 CH 162 
 
8.01 d 8.8 
 
2 3, 4a 2, 14 
  
2 123.6 CH 159 
 
7.35 t 7.8 
 
1, 3 1a, 4 1 
  
3 124.7 CH 159 
 
7.41 t 7.8 
 
2, 4 1, 4a 4 
  
4 110.4 CH 163 
 
7.61 d 8.1 
 
3 1a, 2 3, 6, 15 
  
4a 138.8 
          
  
6 85.0 CH 160 
 
5.94 d 1.7 
 
7 7, 7a, 12b, 15 4, 7, 15 
  
7 71.7 CH 149 
 
5.06 d 1.6 
 
6 6, 7a, 12a, 16 6, 16 
  
7a 109.7 
          
    
7b 126.4 
          
    
8 120.2 CH 164 
 
7.59 d 8.6 
 
9 10, 11a 9, 16 
    
9 124.7 CH 167 
 
7.33 dd 8.3, 1.4 
 
8, 11* 7a, 11 8 
    
10 117.9 
          
    
11 115.6 CH 168 
 
7.76 d 1.7 
 
9* 7b, 9, 10 NH 
    
11a 137.0 
          
    
12a 126.9 
          
    
12b 133.2 
          
    
13 112.3 
          
    
14 185.1 CH 176 
 
10.39 s 
   
12b, 13 1 
    
15 56.8 CH3 144 
 
3.30 s 
   
6 4, 6 
    
16 56.4 CH3 144 
 
3.36 s 
   
7 7, 8 
    
NH         11.78 s         11 
 
* Long-range coupling 
             
                
64 
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3.2.4 7-Bromoreticulatine 
7-Bromoreticulatine (63) was obtained as a brown-green solid. Like 
10-bromohomofascalysin A (66) and several closely related compounds, a persistent 
aliphatic compound was observed in the NMR spectra. The molecular formula for 
7-bromoreticulatine (63) was determined by positive ion mode HRESIMS as C19H14N2O2Br+ 
(m/z 381.0233, [M]+,  -1.6 ppm) and again, the presence of bromine was demonstrated by 
the distinctive [M + 2]+ peak. Similarly to 66, the molecular formula required 13.5 double 
bond equivalents; again this, in conjunction with an observed [M]+ peak suggested that the 
compound was a natively charged species. Thus, the structure elucidation of 
7-bromoreticulatine (63) was carried out under the assumption that the carbon framework 
was similar to that of 10-bromohomofascaplysin A (66).  
Two resonances were of particular interest in the 1H NMR spectrum: a highly deshielded 
aromatic proton singlet at H 9.78 (CH-1; C 132.1), and a deshielded methoxy singlet at 
H 3.68 (CH3-17; C 52.8) which was slightly less shielded than the methoxy singlets present 
in compounds 64 and 65. In addition to these two protonated carbons, the HSQC spectrum 
revealed nine aromatic methines, to give a total of 13 of the 14 protons, and meant the 
presence of one exchangeable proton. Accounting for only 11 protonated carbons, this 
indicated that eight carbons were non-protonated. Six of these carbons could be identified in 
the 13C NMR spectrum which were attributed to five non-protonated aromatic carbons 
(C 143.0, 132.8, 127.3, 125.8, 118.0), and an ,-unsaturated ester carbonyl (C-16; 
C 163.6). The chemical shifts of the two non-protonated carbons unaccounted for in the 
13C NMR spectrum were established from observed HMBC correlations, to be C 147.5 and 
C 136.9. 
Structure elucidation was carried out using the same approach used for 64–66. The terminal 
aromatic 1,2-di- and 1,2,4-trisubstituted rings were again present in this structure, as 
determined by analysis of the COSY and HMBC data. The 1,2,4-trisubstituted ring again 
presented the bromine at position 4 of the aromatic ring (C-7, C 118.0) and in light of the 
previous structures, was presumed to be a bromo-indole ring system. A new observation in 
the 1,2-disubstituted aromatic ring, was an HMBC correlation from H-12 (H 8.28, C 132.5) 
to the ,-unsaturated ester carbonyl carbon, C-16. Other HMBC correlations to C-16 were 
from the deshielded methoxy, CH3-17, validating the ester functionality, and a weak four-
bond HMBC correlation from H-15 (H 7.59, C 128.0). These observed COSY and HMBC 
correlations provided the methylbenzoate substructure outlined in Figure 3.14. 
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Figure 3.14. COSY and HMBC correlations establishing the connectivity between C-10 and 
CH3-17 in 7-bromoreticulatine (63). 
A long range COSY correlation was observed between H-1 and H-3 (H 8.01, C 130.7), 
indicating a close proximity between the two protons. Additionally, one further strong 
correlation between H-3 and H 4 (H 8.34 C 115.4) was noted. Together, the COSY 
correlations suggested a 1,3,4-trisubstituted ring, signifying the loss of the pentacyclic ring 
system observed in compound 66. The 1JCH of CH-1 was considerably large at 199 Hz and a 
similarly large coupling constant was observed for CH-3 at 197 Hz. Assuming again a 
pyridinium cation, the large 1JCH coupling constants implied that H-1 and H-3 were adjacent 
to the quaternary ammonium centre, occupying the - positions and further suggested a 
disconnection of the bond between C-12b and C-13, as found within 
10-bromohomofascaplysin A (66). Observed two-bond and three-bond HMBC correlations 
from H-1, H-3, and H-4, established a link to the bromo-indole substructure across the bond 
between C-4a and C-8a. One further correlation from both H-1 and H-3 to non-protonated 
aromatic carbon C-10 (C 143.0) indicated connectivity to the substructure illustrated in 
Figure 3.14. This observation provided confirmation that the C-12b to C-13 bond had indeed 
been severed. In accordance with the molecular formula and the number of double bond 
equivalents, all requirements were satisfied. Validation towards the structure was ascertained 
through the NOESY data. The overall structure of 7-bromoreticulatine (63) is provided in 
Figure 3.15 with NMR data illustrated in Table 3.6. 
 
Figure 3.15. COSY, HMBC and key NOESY correlations establishing the structure of 
7-bromoreticulatine (63). 
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Table 3.6. 13C (150 MHz) and 1H (600 MHz) NMR data (CDCl3) for 7-Bromoreticulatine (63). 
  
 
 
  13C     1H     HMBC   
   
Pos (ppm) mult J (Hz)   (ppm) mult J (Hz)   COSY (1H to 13C) NOESY 
 
 
 
  
1 132.1 CH 199 
 
9.78 br s 
  
3* 3, 4a, 10 15 
   
3 130.7 CH 197 
 
8.01 d 6.3 
 
1*, 4 1, 4, 4a, 10 4 
   
4 115.4 CH 173 
 
8.34 d 6.5 
 
3 3, 9a 3, 5 
   
4a 132.8 C 
         
   
4b 127.3 C 
         
   
5 123.3 CH 166 
 
8.08 d 8.5 
 
6 4a, 4b, 7, 8a 6 
   
6 125.4 CH 172 
 
7.52 dd 7.8, 1.4 
 
5 4b, 8 5 
   
7 118.0 C 
         
  
 
  
8 117.9 CH 174 
 
8.19 s 
   
4b, 6, 7 
 
  
 
  
8a 147.5 C 
         
  
 
  
9a 136.9 C 
         
  
 
  
10 143.0 C 
         
  
 
  
11 125.8 C 
         
  
 
  
12 132.5 CH 172 
 
8.28 dd 7.8, 1.4 
 
13 10,14,16 13 
  
 
  
13 131.6 CH 167 
 
7.79 td 7.7, 0.9 
 
12, 14 11, 12, 15 12 
  
 
  
14 134.3 CH 168 
 
7.82 td 7.7, 1.3 
 
13, 15 10, 12 
 
  
 
  
15 128.0 CH 169 
 
7.59 d 7.3 
 
14 10, 11, 13, 16* 1 
  
 
  
16 163.7 C 
         
  
 
  
17 52.8 CH3 148 
 
3.68 s 
   
16 
 
 
 * Long-range coupling 
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A combination of 1D and 2D NMR experiments was successfully used to ascertain the 
structures of compounds 61–66. In particular, the NOESY experiment was imperative to the 
validation of the position of the bromine in compounds 63–66. 
3.3 Biological Activity  
7-bromoreticulatine (63), 10-bromo-6,7-dimethoxyhomofascaplysin C (64) and D (65), 
and10-Bromohomofascalysin A (66), and were submitted to the School of Biological Sciences, 
VUW for cytotoxicity analysis against human leukaemia (HL-60) cell lines. 
10-Bromohomofascaplysin (66) A and 7-bromoreticulatine (63) exhibited quite potent 
cytotoxicity with respective IC50 values of 33.8 and 498 nM. 
10-Bromo-6,7-dimethoxyhomofascaplysin C (64) and D (65) were less active displaying 
moderate cytotoxicities with IC50 values of 6.0 and 2.7 M respectively. In regards to the 
structure-activity relationship (SAR), this result perhaps suggests that the presence of the 
pyridinium N-cation is required for activity. 
3.4 Hemiaminal Ether Functionality: Spectral Characteristics 
The hemiaminal ether moiety found in 64 and 65 prompts further discussion as the two 
compounds appear to present a new sub-class of naturally-derived compounds within the 
fascaplysin family. The sole HMBC correlation from methoxy CH3-17, to the methine CH-6, 
created no reservations about a direct link between them, but certain aspects of the NMR data 
suggested that CH-6 was not a typical oxymethine. The highly deshielded carbon and proton 
resonances and the unusually large 1JCH value of CH-6 encountered in both 
10-bromo-6,7-dimethoxyhomofascaplysins C (64) and D (65) were salient features leading 
to questionable functionality. Acetal and epoxide functionalities were discounted due to 
reasons outlined in Chapter 3.2.2. Taking into account the molecular formulae of 64 and 65, 
hemiaminal ether functionality was postulated.  
Comparison of the 1H and 13C Chemical Shifts  
The dimethoxy functionality encountered in 64 and 65 is to the author’s knowledge, an 
unprecedented feature among related, naturally-derived compounds, though the semi-
synthetic analogues 67 and 68†† are almost identical to 64 and 65. The diastereoisomers, 67 
                                                   
†† 6,7,12,12b-tetrahydro-6,7,12b-trimethoxy-13H-pyrido[1,2a;3,4b’]diindole-13-one.  
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and 68 were each obtained as mixtures of inseparable enantiomers‡‡ from the reaction of the 
related compound fascaplysin (69) with NaOMe in MeOH.78 In d6-DMSO, the hemiaminal 
carbon and proton (CH-6) of 67 (trans- diastereoisomer), resonated at C 91.2 and H 4.77; 
compound 68 (cis- diastereoisomer) displayed a relative upfield and downfield shift for the 
carbon and proton respectively, at C 86.8 and H 5.68.78 Compound 67 shows a 
considerable difference in the NMR data for positions CH-6 and CH-7, when compared with 
64 and 65, while 68 displays only a slight difference (Table 3.7). The more favourable 
agreement of the 1H and 13C NMR data (CH-6 and CH-7) between 68 and compounds 64 
and 65, supports the assignment of cis- stereochemistry for 64 and 65. The decreased rigidity 
within the fused cyclic system of compounds 67 and 68, may potentially affect the chemical 
shifts and could account for the slight differences observed between the NMR data of the 
natural products (64 and 65) and compound 68.  
 
   
Table 3.7. Calculated Difference in the 1H and 13C NMR Chemical Shifts at Positions 6 and 7 
between 64, 65, 67 and 68. 
 
 H    C  
 Pos 64 67 68  64 67 68 
64* 6  +1.28 +0.37  
-2.1 -8.3 -3.9 
7  +0.33 +0.27 
 
-0.1 -3.2 -1.8 
65 
6 +0.11 +1.17 +0.26 
  
-6.2 -1.8 
7 -0.07 +0.40 +0.34 
  
-3.1 -1.7 
* Difference calculated from NMR data recorded in d6-DMSO 
More support for the hemiaminal ether functionality is obtained from an analysis of the NMR 
data of the aminal and hemiaminal ether centres found in colensolide A (70). The respective 
1H and 13C chemical shifts of the aminal centre, CH-9 in colensolide A (70) are H 4.54 and 
C 75.8 (d6-DMSO), while the chemical shift of the quaternary hemiaminal carbon, C-13 is 
significantly more deshielded at C 97.5.79 Thus, compound 70 demonstrates the differences 
                                                   
‡‡ For simplicity, the structures of 67 and 68 illustrate only one of the enantiomers. 
(±) 67 (±) 68 69 
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in the effects of oxygen and nitrogen deshielding. Owing to a higher electronegativity, 
oxygen exerts a larger inductive effect than nitrogen; consequently, a hemiaminal ether 
carbon experiences greater deshielding than an aminal carbon. Considering this effect, it is 
logical to expect the chemical shift of a tertiary hemiaminal carbon, to be observed in 
between those reported for C-9 and C-13, in colensolide A (70). Indeed, this is found to be 
the case for the 13C NMR chemical shift of CH 6 in both 64 and 65. This assumption is invalid 
when comparing the relative chemical shifts of aminal and hemiaminal ether protons, as 
protons in general are more susceptible to deshielding caused by inductive effects, as well as 
other factors such as anisotropic and neighbouring group effects; these effects can all cause a 
significant alteration in the chemical shift.77, 80 This is exemplified by the considerable 
difference in the proton chemical shifts observed for CH-6, between diastereoisomers 67 and 
68, and is further illustrated by the close agreement of the proton chemical shifts of the 
hemiaminal ether proton in 67, and the aminal proton in colensolide A (70).  
 
 
The 1JCH Coupling Constant 
The one-bond proton-carbon coupling constant (1JCH) is a parameter that can be used in 
conjunction with the 1H and 13C NMR chemical shifts for added support towards a proposed 
functionality. Like chemical shifts, a given functional group typically reveals a characteristic 
1JCH coupling constant.76 In addition to the 1H and 13C NMR chemical shift, the 1JCH value 
found for CH-6 in 10-bromo-6,7-dimethoxthyhomofascaplysins C (64) and D (65) 
suggested that the functional group was not representative of an oxymethine. A comparison 
against the 1JCH coupling constants of the hemiaminal ether centre of compounds 67 and 68 
would have been ideal, however, the 1JCH values for these compounds were not reported. 
Instead, a comparison was made against the aminal 1JCH in colensolide A (70). The 1JCH 
coupling constant of CH-9 in colensolide A is 162 Hz,79 which is identical to that observed 
for CH-6 in 65 (d6-DMSO) and extremely close to that found for CH-6 in 64 (160 Hz, 
CDCl3). Admittedly, the comparison is made between an aminal and hemiaminal ether 
functional group and the similarity may not appear to be particularly applicable, especially 
since electron withdrawing groups increase the 1JCH value,77 and therefore an aminal should 
exhibit a lower 1JCH value than that of a hemiaminal ether. However, large one-bond 
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coupling constants are generally observed in strained ring systems76 and the comparable 1JCH 
values could be justified by this. Given that CH-9 in compound 70 is positioned at the 
junction of a strained cis-fused bicyclic system, it is likely that the 1JCH value exhibited by 
CH-9 in colensolide A (70) is larger than an average aminal 1JCH.value. As such, the observed 
1JCH values for CH-6 in 10-bromo-6,7-dimethoxyhomofascaplysins C (64) and D (65) are 
assumed to be valid for a hemiaminal ether functionality. 
A search through the literature sought to determine the validity of hemiaminal ether 
functionality in 10-bromo-6,7-dimethoxyhomofascaplysins C (64) and D (65). The NMR 
data of the hemiaminal ether centres of 64 and 65 was compared against compounds 67 and 
68. Compound 68 agreed more favourably with the observed NMR data for CH-6 and CH-7 
in 64 and 65, providing support towards the proposed functionality and the tentatively 
assigned cis- stereochemistry. An analysis of the carbon chemical shifts of CH-9 and C-13 in 
colensolide A (70) as well as the rationalisation of the comparable 1JCH value for CH-9, 
further supported the proposed hemiaminal ether functionality in 64 and 65.  
3.5 Homofascaplysins: Artefacts of Isolation?  
It is possible that the methyl ketone functionality described in this report for 
10-bromohomofascaplysin A (66), is the result of nucleophilic addition by acetone to 
10-bromofascaplysin (71) (Scheme 3.2).  
 
Scheme 3.2. Nucleophilic addition of acetone to 10-bromofascaplysin (71). 
The non-brominated analogue of 66, homofascaplysin A (72), was first reported in 1991 
together with the monoanionic sesterterpene counter-ion, dehydroluffariellolide (73) from 
the Fijian sponge, Fascaplysinopsis reticulata.81 Optical activity was observed for the 
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compound ([]    = -9.4o; c 6.4   10-3, MeOH), indicating the absence of a racemic mixture 
and thereby suggesting the compound to be a natural product.81 Very recently, the 
brominated analogue, 3-bromohomofascaplysin A (74) was isolated from the Fijian ascidian 
Didemnum sp. and its specific rotation was calculated to be []    = -9.0o (c 0.1, MeOH).73b 
Neither of the purification procedures used to isolate 72 or 74 used acetone and the optical 
rotation suggests that homofascaplysin A is not an artefact of isolation. Surprisingly, more 
than a decade after the report of homofascaplysin A,81 Crews et al. reported that the re-
examination of a natural sample of homofascaplysin A (chloride counter-ion, 75) gave a 
specific rotation []    = 0o, indicating that a non-enzymatic reaction could afford racemic 
homofascaplysin A.75 As the counter ion is a chloride ion, it is assumed that the sample is not 
identical to the original sample of homofascaplysin A, they described in 1991.  
 
 
 
 
 
During early purification methods, acetone was used in the isolation of 
10-bromohomofascaplysin A (66). The specific rotation calculated for 66        = +154o; 
c 6.5   10-3, MeOH) is markedly different from the literature values reported for 72 and 74. 
This discrepancy may be due to a contribution of optical activity from the impurities present 
in 10-bromohomofascaplysin A (66). An attempt to determine whether compound 66 is a 
naturally-derived product or an artefact of isolation began with the re-extraction (twice 
overnight in MeOH) of a small amount of PTN4_08E (20 g). The extracts were subsequently 
cyclic loaded onto HP20 reversed-phase packing beads and the column was batch eluted 
with 75%, 90% H2O/MeOH, 100% MeOH and finally 100% THF. Although aromatic proton 
resonances were observed in the 1H NMR spectra of the 100% MeOH and THF fractions, they 
were few and were determined to be non-fascaplysin proton resonances. In contrast, the 
73 
72 R = H X = 73- 
74 R = Br X = Cl 
75 R = H X = Cl 
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1H NMR spectra of the 75% and 90% MeOH fractions showed several aromatic proton 
resonances similar to those observed for the fascaplysins.  
Due to the presence of a singlet close to H 1.90, the 75% was selected for further purification 
on DIOL and the column was eluted with DCM, 20%, 40% DCM/MeOH, and MeOH; the 
1H NMR spectra showed that the aromatic resonances were confined to the 20% and 40% 
DCM/MeOH fractions. Combinations of 1D and 2D NMR experiments were performed on 
the 90% MeOH/H2O (HP20), and 20%, 40% DCM/MeOH (DIOL) fractions. The NMR spectra 
of the 20% DCM/MeOH fraction revealed the familiar 1,2-di-, 1,2,4-tri- and 
1,2,3,4-tetrasubstituted aromatic rings observed in compound 66, in addition to a methyl 
singlet and methylene which both correlated to a ketone at C 209.1 in the HMBC spectrum. 
However, the methylene further correlated to other methylene carbons and no correlation to 
a quaternary carbon was observed. Analysis of the 40% DCM/MeOH fraction NMR data, 
showed that the aromatic proton resonances were attributed to a compound, whose cyclic 
carbon framework resembled 7-bromoreticulatine (63); no ketone resonance was observed. 
The ketone resonance was also absent from the NMR data of the 90% MeOH HP20 fraction. 
Additionally, the NMR spectra of these three fractions also lacked evidence for the ,-
unsaturated ketone found in 10-bromofascaplysin. Since no evidence for the presence of 
either 10-bromohomofascaplysin A (66) or 10-bromofascaplysin (71) could be found in the 
NMR data, the answer to this question remains inconclusive.  
As mentioned earlier, 10-bromo-6,7-dimethoxyhomofascaplysins C (64) and D (65) 
represent a new sub-class within the fascaplysin family. The closest analogues that exist in 
the literature are the semi-synthetic compounds, 67 and 68.78 Although methanol was used 
extensively throughout the isolation protocol, it seems unlikely that the relatively mild 
conditions of the PSDVB and DIOL packing materials used for purification were enough to 
induce methoxy addition. Furthermore, if these compounds were susceptible to this addition 
under mild conditions, there would surely be precedence for this functionality among the 
reported fascaplysin derivatives, since methanol has been used just as extensively in the 
isolation of all compounds reported thus far.72, 73, 75, 81, 82 Nonetheless, it cannot be stated with 
absolute certainty that 64 and 65 are indeed natural products. Despite the specific rotation 
calculated for 65 being       = 0o (c 3.0   10-4, CHCl3), this result is unreliable due to such a 
low concentration and the specific rotation calculated for 64, is irrational and invalid 
     
  = -2222o; c 5.0   10-4, CHCl3) also due to the low concentration. More work is 
required to determine the answer to this question, whereby the sponge should be re-
extracted and purification methods carried out in the absence of methanol. Ethanol would 
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provide a convenient substitute, as ethoxy substituents would be expected to replace the 
methoxy groups if compounds 64 and 65 are indeed artefacts.  
3.6 Related Bis-indole Alkaloids 
Fascaplysin (69) is an intensely red pigmented bis-indole alkaloid reported in 1988 by 
Clardy et al., along with the known compound luffarielolide (62) from the Fijian sponge 
Fascaplysinopsis sp., Berquist.72 Prior to this, Fascaplysinopsis reticulata was well known for 
the monomeric tryptophan derived compound, aplysinopsin (76) but the 
12H-pyrido[1,2-a;3,4-b’ ]diindole system of fascaplysin (69) presented a new precedent to 
natural products. X-ray diffraction analysis gave the complete structure of fascaplysin after 
NMR could not effectively eliminate other potential structures due to the unfavourable ratio 
H:CNO of 0.52 providing ambiguous assignments.72 A total of 24 related compounds have 
subsequently been isolated from Fascaplysinopsis sp., Hyrtios sp., and Thorectandra sp. 
sponges and Didemnum sp. tunicates.73a Sponges representing the genus Fascaplysinopisis 
have provided several of these unusual bis-indole alkaloids. 
F. reticulata collected from Fiji, yielded fascaplysin A (77), homofascaplysin A (72), and 
reticulatine (78) alongside the sesterterpenoids dehydroluffariellolide (73) and 
isodehydroluffariellolide (79). As with 72, compound 77 was also accompanied by the 
monoanionic form of the sesterterpene compound 73. Subsequent purification of fascaplysin 
A (77) on anion exchange resin (DOWEX-1, chloride) afforded fascaplysin (69). Unlike 
fascaplysin (69) and fascaplysin A (77) the literature does not attempt to make a distinction 
between the names of the two forms of homofascaplysin A (one containing the chloride 
counter ion and the other a sesterterpene counter ion). A thorough investigation of the 
sponge led to the isolation of neutral compounds homofascaplysin B (80), homofascaplysin C 
(81), and secofascaplysin A (82).81, 82 More than a decade later, the same research group 
reported the isolation of reticulatate (83) from a different collection of F. reticulata.75 
Reticulatate (83) had been reported a year earlier as an isolate from a Palauan sponge 
identified as a Thorectandra sp.,82b though a synthetically derived zwitter-ionic analogue 
obtained from the reaction of fascaplysin (69) with 1 M NaOH or with 30% aqueous NH4OH 
was the first to appear in the literature.78 Continued investigations of 12 separate sponge 
specimens of F. reticulata collected from various sites off the coasts of Fiji and Indonesia 
provided the congeners homofascaplysate A (84), reticulatol (85) along with brominated 
analogues of those mentioned: 10-bromofascaplysin (71), 3-bromofascaplysin (86), 
3,10-dibromofascaplysin (87), 14-bromoreticulatine (88), 7,14-dibromoreticulatine (89), 
 69 
 
14-bromoreticulatate (90), 14-bromoreticulatol (91), and 3-bromosecofascaplysins A and B 
(92 and 93, respectively).73a, 75 
The genus Fascaplysinopsis has clearly yielded many fascaplysin derivatives, but they have 
not been exclusively found within this genus. Both homofascaplysin A (75) and fascaplysin 
(69) have been isolated from a Fijian collection of the sponge Hyrtios cf. erecta.83 
Investigations on the sponge Thorectandra sp. resulted in the isolation of thorectandramine 
(94) alongside fascaplysin (69), reticulatine (78), and reticulatate (83).82b, 82c 
Thorectandramine (94) is unlike other analogues of fascaplysin, as it bears a sixth aromatic 
ring substituted on C-13. Didemnum sp. ascidians have additionally yielded fascaplysin (69), 
homofascaplysin C (81), homofascaplysate A (84), and 3-bromofascaplysin (86).73a The 
fascaplysin derivatives, 3-bromohomofascaplysin A (74), 3-bromohomofascaplysin B (95), 
3-bromohomofascaplysin C (96), homofascaplysin B-1 (97), and 3-bromohomofascaplysin 
B-1 (98) were also isolated from Didemnum sp. ascidians and are yet to be discovered from 
sponges.73  
One feature that appears to be rare among the group of fascaplysin derivatives is 
monobromination on the A-ring. Of the 24 compounds documented in the literature, 11 are 
brominated analogues, yet only three display A-ring bromination. A closer inspection shows 
that of these three, just one is monobrominated. The sponge investigated in this research 
provided only A-ring monobrominated analogues and may hold prospective for the isolation 
of several more structures of this kind.  
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All compounds have shown varying degrees of bioactivity, in a number of different biological 
assays. Given that several compounds have been re-isolated, by more than one research 
group and hence a variety of bioassays performed, only the few which have shown to exhibit 
cytotoxicity will be discussed. An in vitro disk diffusion soft agar assay was used to identify 
solid-tumour selectivity of fascaplysin (69), 10-bromofascaplysin (71), reticulatine (78) 
reticulatate (83), reticulatol (85), 3-bromofascaplysin (86), 14-bromoreticulatine (88), 
7,14-bromoreticulatine (89), 14-bromoreticulatate (90), and 14-bromoreticulatol (91).73a 
The cytotoxicity against murine and human solid-tumour, leukaemia and normal cells was 
measured for each compound and solid-tumour selectivity was determined by calculating 
the difference in cytotoxicity between solid-tumour and leukaemia, and solid-tumour and 
normal cells; compounds with a difference equal to or greater than the standard used in the 
assay were considered as “tumour selective”.73a Fascaplysin (69) was found to be the most 
cytotoxic and showed selectivity towards murine solid-tumour cell lines (0.4 g/disk). 
Reticulatine (78) also displayed selectivity towards murine solid-tumour cell lines although 
at a concentration 45 times higher (18 g/disk) than that observed for fascaplysin (69). 
Conversely, selectivity towards human solid-tumour cell lines was found from 
10-bromofascaplysin (71) (0.8 g/disk) while 3-bromofascaplysin (86) displayed no 
selectivity in either the murine or human cell lines (6.4 g/disk). This result suggested that 
the placement of the bromine within the fascaplysin framework plays a role in the activity. 
Compared with reticulatine (78), the presence of the bromine in 14-bromoreticulatine (88), 
and 7,14-bromoreticulatine (89) caused a significant decrease in the cytotoxicity and a loss 
of selectivity (200 and 84 g/disk, respectively). Reticulatate (83) was observed to be selective 
for both murine and human solid-tumour cell lines (64 g/disk) while 14-bromoreticulatate 
(90) was not selective towards either (64 g/disk). Interestingly, reticulatol (85) and 
14-bromoretulatol (91) exhibited selectivity towards human leukaemia (64 and 84 g/disk, 
respectively).73a Fascaplysin (69), fascaplysin A (77), and 3-bromofascaplysin (86) were also 
tested for in vitro antitumour activity against 60 human cancer cell lines. The overall results 
showed 69 and 77 to be approximately equally active, but surprisingly, in many cell lines 
where fascaplysin (69) was inactive, the presence of the sesterterpene anion in fascaplysin A 
(77) caused activity. In contrast, 3-bromofascaplysin (86) was found to be more cytotoxic 
than 69 and 77 but was inactive in cell lines that were sensitive to 69 and 77.73a Reticulatine 
(78) was also found to be moderately active against breast (MCF-7) and ovarian cancer 
(OVCAR-3) cell lines with IC50 values of 1.5 and 2.2 mg/mL, respectively; reticulatate (83) 
displayed moderate activity against the MCF-7 cell line only (IC50 5.9 mg/mL).82b There 
appears to be no information on the cytotoxicity of homofascaplysin A (75) in the literature 
although it is reported to display growth inhibition against the chloroquine- and 
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pyrimethamine-resistant Plasmodium falciparum (malaria inducing parasite) strain K1, with 
an IC50 value of 38 nM.73b  
3.7 Biogenetic Relationship between Fascaplysins 
A biogenesis for compounds 63–66 cannot be postulated without proposing a biogenesis on 
closely related compounds. Currently, there are 24 closely related compounds documented in 
the literature, and thus a biogenesis would be elaborate and beyond the scope of this report. A 
simple biogenetic pathway linking certain members of the fascaplysin family has been 
proposed by Crews et al., which was based upon the general acceptance that they are 
tryptophan-derived secondary metabolites.73a Therefore, this report will not attempt to 
propose a biogenesis but will give a brief depiction of where compounds 63–66 may fit into 
this proposed pathway. 
The putative biogenetic pathway proposed by Crews et al. (Scheme 3.3) provides a 
relationship between the fascaplysin derivatives isolated in that particular study73a and fails 
to include homofascaplysin A (75) and thorectandramine (94), despite the Crews research 
group providing the original report of homofascaplysin A.81 Certainly, 7-bromoreticulatine 
(63) can be easily incorporated within the proposed biogenetic pathway, as the only 
modification from reticulatine (78), is the addition of bromine. It is possible that 
10-bromo-6,7-dimethoxyhomofascaplayin C (64) is derived from a hypothetical 
10-bromohomofascaplysin C. The non-brominated analogue, homofascaplysin C (81) is 
thought to arise from the postulated -keto acid (Scheme 3.3).73a The methyl ketone 
functional group present in 10-bromo-6,7-dimethoxyhomofascaplysin D (65) suggests a 
close biogenetic relationship with 10-bromohomofascaplysin A (66). Homofascaplysate A 
(84) is proposed to arise from fascaplysin (69), although how this might occur is uncertain 
and as such is not depicted in the pathway.73a Since homofascaplysin A (75) and 
homofascaplysate A (84) differ only by the carbonyl functional group at C-16, it is assumed 
that the brominated analogue of 69, 10-bromofascaplysin (71), acts as the precursor to 
10-bromohomofascaplysin A (66), either enzymatically or non-enzymatically. The link 
between 66 and 10-bromo-6,7dimethoxyhomofascaplysin D (65) could possibly occur 
through a hypothetical 10-bromohomofascaplysin D derivative. The overall proposed 
biogenesis adapted from Crews et al. illustrated in Scheme 3.3, includes the new fascaplysin 
derivatives isolated in this study and illustrates hypothetical compounds in blue.  
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Scheme 3.3. Putative biogenetic relationship between fascaplysin derivatives. Adapted from Crews et al.73a  
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Chapter 4 
Conclusion 
Over the last five decades, complex bioactive marine natural products have attracted the 
attention of researchers from many scientific disciplines. The oceans remain a largely 
untapped resource and will continue to supply a considerable number of new and novel, 
architecturally interesting bioactive compounds, with potential as pharmaceutical drugs and 
drug leads, for many years to come.  
This study began with the investigation of four common Tongan holothurians to determine 
whether the antifungal activity exhibited by saponins isolated from Australostichopus mollis 
is unique to the New Zealand sea cucumber, or a generic feature. The Tongan holothurian 
saponins were found to exhibit similar antifungal activity against Saccharomyces cerevisiae, 
to that observed for the A. mollis saponin, neothyonidioside (44), suggesting the antifungal 
activity to be a general characteristic. Since the mechanism of action of neothyonidioside (44) 
in yeast has since been investigated, this result is not surprising, as other saponins are likely 
to have the same mechanism of action.67 
An investigation of Tongan marine sponges involved the screening of five sponge specimens 
using the VUW MNP laboratory NMR spectroscopy screening protocol. By this method, two 
topologically dissimilar sponges were found to be identical early in the investigation which 
may not have been identified until a later stage in a bioassay guided isolation protocol. 
Purification of an unidentified sponge extract resulted in the isolation of three known 
euryspongiol congeners which were found to be mixtures. A thorough investigation of a 
Dictyoceratid sponge yielded four new members of the fascaplysin family. The derivatives all 
contained bromination of the A-ring, which appears to be a rare feature among members of 
the fascaplysin family. The NOESY experiment was essential to the confirmation of the 
 75 
 
bromine position. Perhaps further investigations of a larger collection of this sponge may 
provide additional A-ring brominated analogues to those isolated in this research. Certainly, 
there remains potential for other fascaplysin derivatives to be discovered from the sponge 
which could subsequently enable SAR analyses to be performed. 
Several challenges were encountered during the isolation of these compounds, notably with 
respect to their purification. A long-chain alkyl moiety impurity was persistently present and 
appears to be a common, albeit undesirable feature found alongside the fascaplysin 
derivatives. The isolation of 10-bromo-6,7-dimethoxyhomofascaplysins C and D (64 and 65, 
respectively) present a new sub-class of naturally-derived fascaplysin congeners whose NMR 
chemical shifts and 1JCH in particular, were key factors to the indication of hemiaminal ether 
functionality at CH-6. It remains uncertain whether compounds 64–66 are artefacts of 
isolation, and this must be further investigated to establish the answer to this question. In the 
case of compounds 64 and 65, this answer may be found by re-extraction of the sponge 
specimen but in all instances where methanol is typically used, ethanol should be substituted. 
For compound 66, acetone should be avoided.  
The nanomolar cytotoxicity exhibited by 10-bromohomofascaplysin A (66) and 
7-bromoreticulatine (63) is motivation for their re-isolation, so that their biological 
properties can be thoroughly investigated. Interestingly, compound 66 displayed cytotoxicity 
approximately 200 times greater than 64 and 90 times greater than 65; 63 was roughly 12 
and 5 times more cytotoxic than 64 and 65, respectively. This result suggests that the 
presence of the pyridinium cation may be required for activity. It is important to note, that 
the utilisation of a bioassay guided isolation protocol may have shrouded the isolation of 64 
and 63 as a result of the substantial cytotoxicity exhibited by 63 and 66.  
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Chapter 5 
Experimental 
5.1 General Experimental 
All NMR spectra were recorded using a 600 MHz Varian Direct Drive spectrometer (600 
MHz for 1H nuclei, and 150 MHz for 13C nuclei) equipped with a triple resonance HCN 
cryogenic probe operating at 25 K. The residual solvent peak was used as an internal 
reference for 1H and 13C chemical shifts.84 Quantification of 1H NMR samples was performed 
using the acquisition parameters described by West57 with an internal CH3NO2 standard. 
HRESIMS data were obtained from a Waters Q-TOF Premier Tandem Mass spectrometer 
located at Industrial Research Limited. UV-vis spectra were recorded on an Agilent Diode 
Array spectrophotometer. Optical rotations were run on a Rudolph Research Analytical 
Autopol II Automatic polarimeter. 
Solvent mixtures for all chromatography are reported as % v/v. HPLC purifications were 
carried out using a Rainan Dynamax SD-200 solvent delivery system with 25 mL pump 
heads. A Varian Prostar 335 Diode Array detector was used for UV detection of all HPLC 
runs. Solvents utilised in HPLC were of HPLC grade and H2O was glass distilled and deionised 
using a MilliQ system. Normal-phase HPLC was performed using a custom-packed 
Phenomenex analytical (5.0   250 mm, 5 m) or semi-preparative (10   250 mm, 5 m) 
dihydroproproxypropyl-derivatised silica (DIOL) column. Reversed-phase HPLC was 
performed using a Phenomenex Prodigy C18 analytical (4.6   250 mm, 5 m) or semi-
preparative (10    250 mm, 10 m) column. Normal-phase flash column chromatography 
was performed using YMC Co. Ltd DIOL chromatographic resin. Reversed-phase 
chromatography was carried out using Supelco HP20 and HP20ss. Solvents used for bench-
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top chromatography were either glass distilled or of HPLC grade. TLC analyses were 
performed on Machery-Nagel Alugram SIL G/UV254 plates. Analysis of TLC plates was carried 
out by visualisation of (1) absorbance and fluorescence under UV light (λ = 254 nm and 
350 nm respectively), and (2) dipping in 5% H2SO4/MeOH followed by dipping in 0.1% 
vanillin/EtOH (% w/v) then heating. 
5.2 Isolation of Euryspongiols A1, A2 and B from an Unidentified Sponge 
The unidentified sponge PTN4_14B was collected by hand using SCUBA at a depth of ~23 m, 
Northern Vava’u Island, Tonga (18o 36.8’ S, 174o 01.3’ W) in late November 2009, after 
which it was immediately frozen and stored at -18 oC until extraction. A voucher sample was 
prepared in EtOH and is kept at -18 oC at the School of Physical and Chemical Sciences, 
Victoria University of Wellington, New Zealand. 
The sponge (22g; wet weight) was extracted twice overnight with MeOH (100 mL) and 
subsequently cyclic loaded onto a 40 mL HP20 column and then washed with H2O (60 mL). 
The column was eluted with 60 mL of the following: (1) 30% Me2CO/H2O (2) 75% 
Me2CO/H2O and (3) 100% Me2CO. The 100% Me2CO fraction was concentrated to dryness 
under reduced pressure to provide 52.5 mg of material, while the 30% and 75% Me2CO/H2O 
fractions were backloaded onto individual columns packed with HP20 (20 mL). Each column 
was then eluted with Me2CO to give 5.5 mg of the 30% fraction and 33.9 mg of the 75% 
fraction. 
The 75% fraction was cyclic loaded onto HP20ss and then eluted with 20 mL portions of 
MeOH/H2O, beginning with 30% and increasing in 10% increments, until the final elution 
with 100% MeOH. Each fraction was concentrated by rotary evaporation then any remaining 
water was removed by first freezing with liquid N2 and then by lyophilisation. Based on a 
combination of TLC (20% MeOH/DCM) and NMR analyses, the 70%-100% fractions were 
combined and chromatographed on a DIOL column (10 mL). The column was eluted with 
20 mL solutions of DCM, 2.5%, 5%, 7.5%, 10%, 20%, 50% EtOAc/DCM, then 50% 
DCM/MeOH, however no separation was achieved. All fractions were combined and an 
attempt to purify approximately half of the sample on silica (10 mL) was ineffective as the 
majority of the sample did not elute from the silica column. Chromatography on a DIOL 
column (10 mL) was re-attempted, using the remainder of the 75% Me2CO/H2O fraction. The 
column was eluted with the following: EtOAc, 1%, 2%, 5%, 7.5% 10%, 20% 50% 
MeOH/EtOAC and finally Me2CO. Fractions were combined based on TLC analysis with the 
mobile phase 20% MeOH/DCM. The polar fraction (eluting from 20% MeOH/EtOAc) was 
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further purified on an analytical C18 HPLC column eluting with 60% H2O/MeCN at a flow 
rate of 1 mL/min. Four fractions were collected and two fractions each contained a mixture 
of closely related compounds. Fraction 2 (retention time 3.5 min) gave 0.2 mg of material 
containing a mixture of euryspongiol A1 (51) and another compound believed to be closely 
related to 51 (approximate ratio 1.6:1, respectively) though spectral data was either far too 
weak or absent to allow for structure elucidation of the second compound. Fraction 3 
contained 1.3 mg of sample which was a mixture of euryspongiols A2 (52) and B (53) in an 
approximate ratio of 2:1, respectively. 
Euryspongiol A1 (51): White solid; NMR data in agreement with those published.69 
Euryspongiol A2 (52): White solid; NMR data in agreement with those published.69 
Euryspongiol B (53): White solid; all NMR data in agreement with those published.69 
5.3 Isolation of Bis-indole Alkaloids from a Dictyoceratid Sponge 
Two separate collections of the same sponge, PTN4_08E and PTN4_10B, were obtained by 
hand using SCUBA at a depth of approximately 15 m, from Fakafotula Island, Vava’u, Tonga 
(18o 39.6’ S, 174o 04.2’ W) in late November 2009. The specimens were frozen immediately 
and stored at -18 oC until extraction. A voucher sample is kept at the School of Chemical and 
Physical Sciences, Victoria University of Wellington, New Zealand, stored in EtOH at -18 oC.  
The sponge (92 g; wet weight) was cut into small pieces and extracted twice overnight with 
MeOH (2 x 500 mL). The extracts were cyclic loaded onto a glass column packed with HP20 
beads (200 mL) and the column was subsequently washed with H2O (600 mL). Elution of the 
column was performed with 300 mL of each of the following: (1) 30% Me2CO/H2O, (2) 75% 
Me2CO/H2O and (3) 100% Me2CO. Fractions 1 and 2 were backloaded onto separate 
columns packed with HP20 beads (100 mL) and subsequently eluted with Me2CO (250 mL). 
The three organic eluents were concentrated to dryness under reduced pressure to afford 
108.0 mg of fraction 1, 296.2 mg of fraction 2, and 677.1 mg of fraction 3. Each fraction was 
analysed by TLC and NMR, the latter revealing interesting aromatic resonances confined to 
the 100% Me2CO HP20 fraction. 
Fraction 3 was loaded onto DIOL (60 mL) and the column was eluted with the following: 
20 mL mixtures of pet. ether, 1%, 2%, 5%, 10%, 20%, 50% DCM/pet. ether, DCM, 1%, 2%, 5%, 
10%, 20%, 50% EtOAC/DCM, EtOAc, 1%, 2%, 5%, 10%, 20%, MeOH/EtOAc, and 400 mL of 
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50% MeOH/DCM. The DIOL remained coloured and was consequently eluted with 10% 
H2O/MeOH (1 L) over 3 days. Fractions were combined based on TLC evidence. 
By 1H NMR analysis, ambliol B (61, 4.5 mg) was found in the combined fractions eluted from 
20% DCM/pet. ether and luffariellolide (62, 147.6 mg) was discovered in the fractions eluted 
from 5% EtOAc/DCM. The 10% H2O/MeOH fraction contained 5.1 mg of 
7-bromoreticulatine (63). The 50% MeOH/DCM DIOL fraction was revealed by 1H NMR to 
contain more of the aromatic resonances of interest and further purification was continued 
on DIOL (10 mL), eluting with 30 mL portions of DCM, 20%, 40%, 80% MeOH/DCM and 
finally MeOH. Again the fractions were combined on the basis of TLC analysis.  
Purification of the combined fractions eluting from the DIOL column from 20% MeOH/DCM 
was attempted on an analytical C18 HPLC column, eluting with 50% MeCN/0.1 M HCOOH 
(aq), then 40% MeCN/0.1 M HCOOH(aq), followed by 25% MeCN/0.05 M HCOOH. These 
conditions proved to be unsuitable, determined by the UV trace which showed the 
chromophore streaking. Consequently, the sample was purified on an analytical DIOL HPLC 
column and eluted with 20% IPA/n-hexane at a flow rate of 1 mL/min, then stripped with 
80% IPA/n-hexane. Three fractions were collected, fraction 1 (retention time 6.4 min) 
afforded 10-bromo-6,7-dimethoxyhomofascaplysin C (64, 128 g), and fraction 2 
(retention time 7.5 min) yielded 10-bromo-6,7-dimethoxyhomofascaplysin D (65, 83 g). 
The final fraction which eluted from 80% IPA/n-hexane was re-chromatographed on an 
analytical C18 HPLC column and eluted from 30% MeCN/0.5 M HCOOH(aq) at a flow rate of 
1 mL/min. One fraction was collected (retention time 2.5 min) which was subsequently cyclic 
loaded onto HP20ss and eluted with 15 mL MeOH to yield 651 g of 
10-bromohomofascaplysin A (66). 
Ambliol B (61): Red-brown oil;       = +67.6o (c 5.9   10-2, CHCl3); all spectroscopic data 
were in agreement with those previously published.70 
Luffariellolide (62): Brown oil;       = +4.9o (c 1.0, CHCl3); all spectroscopic data were in 
agreement with those previously published.71 
10-Bromohomofascaplysin A (63): Yellow solid;       = +154o (c 6.5   10-3, MeOH); UV 
(MeOH) max (log ) 215 nm (4.54), 264 nm (4.41), 347 nm (4.32); NMR data presented in 
Tables 3.1 & 3.2; HRESIMS obsd. m/z 407.0395 : 409.0382 (1 : 1, [M]+ : [M+2]+), 
C21H16N2O2Br+, calcd. 407.0395 : 409.0370,  0.0 ppm. 
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10-Bromo-6,7-dimethoxyhomofascaplysin C (64): Yellow solid;       = -2222o (c 5.0   10-4, 
CHCl3); UV (MeOH) max (log ) 6.38 x 10-6 242 nm (4.64), 355 nm (4.50), 375 nm (4.52); 
NMR data presented in Table 3.5; HRESIMS obsd. m/z 423.0348 : 425.0347 (1 : 1, [M-H]- : 
[M+2-H]-) , C21H16N2O3Br, calcd. 423.0344 : 425.0329,  0.9 ppm. 
10-Bromo-6,7-dimethoxyhomofascaplysin D (65): Yellow solid;       = 0o (c 3.0   10-4, 
CHCl3); UV (MeOH) max (log ) 228 nm (4.62), 260 nm (4.44), 393 nm (4.33); NMR data 
presented in Tables 3.3 & 3.4; HRESIMS obsd m/z 451.0654 : 453.0664 (1 : 1, 
[M-H]- : [M + 2 - H ]-), C23H20N2O3Br, calcd. 451.0657 : 453.0642,  -0.7 ppm. 
7-Bromoreticulatine (66): Brown-yellow oil; UV (MeOH) max (log ) 207 nm (4.88), 252 nm 
(4.62), 322 nm (4.43); NMR data presented in Table 3.6; HRESIMS obsd. 
m/z 381.0233 : 383.0215 (1 : 1, M]+ : [M+2]+), C19H14N2O2Br+, calcd. 381.0239 : 383.0213, 
 -1.6 ppm. 
5.3.1 Re-extraction of a Specimen of Sponge PTN4_08B in the Search for 
 10-bromohomofascaplysin A 
A small specimen (21.5 g; wet weight) of PTN4_08E was cut from the parent specimen and 
extracted twice in MeOH overnight (100 mL). The extracts were cyclic loaded onto an HP20 
column (40 mL) and washed with H2O (60 mL). Elution of the column was carried out with 
60 mL of (1) 75% MeOH/H2O (2) 90% MeOH/H2O (3) 100% MeOH and then (4) 100 mL of 
THF. The 75%–100% MeOH/H2O fractions yielded yellow eluents and were concentrated by 
rotary evaporation, then remaining H2O was frozen with liquid N2 and the samples were 
freeze dried to give 17.3, 18.8, 27.0 mg of material of the 75%, 90% MeOH/H2O and 100% 
MeOH fractions, respectively. The THF fraction provided a dark green eluent which was 
backloaded onto an HP20 column (20mL) and the column was washed with H2O. The HP20 
beads were transferred to a round bottom flask (100 mL) and freeze dried. Once dry, the 
beads were washed with DCM (100 mL) by filtration into a Buchner flask (250 mL) 
providing a yellow filtrate that was concentrated under reduced pressure to afford 83.7 mg 
of material.   
The 75% MeOH/H2O fraction was further purified on a DIOL column (10 mL), eluting with 
30 mL portions of DCM, 20%, 40% MeOH/DCM and 100% MeOH. The 1H NMR spectra 
revealed the aromatic resonances as being confined to the 20% and 40% MeOH/DCM 
fractions, however analysis of the 2D NMR data acquired for these fractions lacked evidence 
for the presence of 10-bromohomofascaplysin A (66) and 10-bromofascaplysin (71). 1D and 
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2D NMR data were acquired for the 90% MeOH/H2O HP20 fraction which also showed no 
evidence for either of these compounds.  
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Appendix A 
Existing Marine Chemistry Screening Protocol 
Required apparatus 
 1   Screen column loaded with 40 mL HP20 for Tongan specimens, 80 mL for New 
Zealand specimens, equilibrated in MeOH 
 1   Backloading column loaded with 20 mL HP20 for Tongan specimens, 40 mL for 
New Zealand specimens, equilibrated in MeOH 
Preparation of Nitromethane Quantification Standard 
 Prepare a 0.01% solution (% v/v) by transferring 100 µL CH3NO2 into a 10 mL 
volumetric flask and topping up to 10 mL with d-chloroform. 
Procedure 
1. Preparation of Voucher Sample 
 Take a voucher specimen of approximately 10 g of sponge, ensuring that it is 
representative of both the ectoderm and endoderm.  
 Label and store the voucher sample in 75% isopropanol in water. 
2. Extraction 
 Extract approximately 20 g of crude sponge material in 100 mL MeOH overnight 
(100 g for New Zealand Marine organisms in 400 mL MeOH). 
 Filter the extract and set aside. Re-extract the sponge material (and any filter 
paper/celite) in 100 mL MeOH overnight. 
 Filter the second extract. 
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 Keep all sponge material (including filter paper/celite) until the screen is complete 
at which time it may be discarded. 
3. Cyclic Loading 
 Pass the second extract through the screen column with a flow rate of 
approximately 10 mL/min. 
 Pass the first extract through the screen column with a flow rate of approximately 
10 mL/min. Combine the eluent with that of the second extract. 
 Dilute the combined eluents with 200 mL of distilled water. Pass the diluted eluents 
back through the screen column at a flow rate of approximately 10 mL/min. 
 Dilute the eluent with 400 mL of distilled water. Pass the diluted eluent back 
through the screen column at a flow rate of approximately 10 mL/min. 
 The eluent should be kept until the screen is complete at which time it may be 
discarded. 
4. Elution 
 Elute the screen column with 100 mL of distilled water at a flow rate of 
approximately 10 mL/min. The water eluent can be discarded immediately. 
 Elute the screen column with 100 mL of 30% acetone in distilled water at a flow 
rate of approximately 10 mL/min. 
 Elute the screen column with 100 mL of 75% acetone in distilled water at a flow 
rate of approximately 10 mL/min. 
 Elute the screen column with 100 mL of 100% Me2CO at a flow rate of 
approximately 10 mL/min. 
5. Backloading the 75% Acetone Fraction 
 Dilute the 75% acetone fraction with 100 mL of distilled water. Pass the diluted 
eluent through the backloading column at a flow rate of approximately 8 mL/min. 
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 Dilute the eluent with 200 mL of distilled water. Pass the eluent back through the 
backloading column at a flow rate of approximately 8 mL/min. 
 The eluent should be kept until the screen is complete at which time it may be 
discarded. 
 Elute the backloading column with 100% acetone. 
6. Processing the 75% Acetone Fraction 
 Concentrate the acetone eluent to dryness by rotary-evaporation then transfer to a 
pre-weighed sample vial. If solvent was used for the transfer, concentrate to dryness 
and record the mass. 
 If sufficient mass is obtained, sub-sample approximately 30 mg for NMR analysis. 
 In a 5 mm NMR tube, prepare an NMR sample by dissolving the sub-sample in 
500 µL of CD3OD. 
 Add 10 µL of the nitromethane standard to the NMR tube. 
7. NMR Analysis of the 75% Acetone Fraction 
 Run a 1H NMR spectrum of the sample on the 600 MHz instrument using the 
standard ‘Screen1H’ parameter set (experiment time approximately 4 mins). 
 Make a note “standard added” in the sample text. 
 Run a COSY spectrum of the sample using the standard ‘ScreenCOSY’ parameter set 
(experiment time approximately 20 mins). 
 Run an HSQC NMR spectrum of the sample using the standard ‘ScreenHSQC’ 
parameter set (experiment time approximately 5.5 h). 
8. Backloading the 30% Acetone Fraction 
 Dilute the 30% acetone fraction with 100 mL of distilled water. Pass the diluted 
eluent through the backloading column at a flow rate of approximately 8 mL/min. 
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 Dilute the eluent with 200 mL of distilled water. Pass the eluent back through the 
backloading column at a flow rate of approximately 8 mL/min. 
 The eluent should be kept until the screen is complete at which time it may be 
discarded. 
 Elute the backloading column with 100% acetone. 
9. Processing the 30% Acetone Fraction 
 Concentrate the acetone eluent to dryness by rotary-evaporation then transfer to a 
pre-weighed sample vial. If solvent was used in the transfer, concentrate to dryness 
and record the mass. 
 If sufficient mass is obtained, sub-sample approximately 30 mg for NMR analysis. 
 Prepare an NMR sample in 500 µL of CD3OD in a 5 mm NMR tube. 
10. NMR Analysis of the 30% Acetone Fraction 
 Run a 1H NMR spectrum of the sample using the standard ‘Screen1H’ parameter set. 
11. Processing the 100% Acetone Fraction 
 Concentrate the acetone eluent to dryness by rotary-evaporation then transfer to a 
pre-weighed sample vial. If solvent was used in the transfer, concentrate to dryness 
and record the mass. 
 Prepare an NMR sample in 700 µL CDCl3 in a 5 mm NMR tube. 
12. NMR Analysis of the 100% Acetone Fraction 
 Run a 1H NMR spectrum of the sample using the standard ‘Screen1H’ parameter set. 
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Appendix B 
1H and 13C NMR Spectra of Known Compounds 
 
1H NMR spectrum of Euryspongiol A1 (51) (MeOD, 600 MHz) 
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13C NMR spectrum of Euryspongiol A1 (51) (MeOD, 600 MHz) 
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1H NMR spectrum of Euryspongiols A2 (52; major) and B (53; minor) (MeOD, 600 MHz) 
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13C NMR spectrum of Euryspongiols A2 (52; major) and B (53; minor) (MeOD, 600 MHz) 
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1H NMR spectrum of ambliol B (61) (CDCl3, 600 MHz) 
 
 91 
 
 
 
13C NMR spectrum of ambliol B (61) (CDCl3, 600 MHz) 
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1H NMR spectrum of luffariellolide (62) (CDCl3, 600 MHz) 
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13C NMR spectrum of luffariellolide (62) (CDCl3, 600 MHz) 
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Appendix C 
7-Bromoreticulatine Spectra 
 
1H NMR spectrum of 7-bromoreticulatine (63) (CDCl3, 600 MHz) 
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13C NMR spectrum of 7-bromoreticulatine (63) (CDCl3, 600 MHz) 
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COSY spectrum of 7-bromoreticulatine (63) (CDCl3, 600 MHz) 
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HSQC (coupled) spectrum of 7-bromoreticulatine (63) (CDCl3, 600 MHz) 
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HMBC spectrum of 7-bromoreticulatine (63) (CDCl3, 600 MHz) 
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Appendix D 
10-Bromo-6,7-dimethoxyhomofascaplysin C Spectra 
 
 
1H NMR spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin C (64) (CDCl3, 600 MHz) 
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COSY spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin C (64) (CDCl3, 600 MHz) 
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HSQC (coupled) spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin C (64) (CDCl3, 600 MHz) 
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HMBC spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin C (64) (CDCl3, 600 MHz) 
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Appendix E 
10-Bromo-6,7-dimethoxyhomofascaplysin D Spectra 
 
1H NMR spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin D (65) (CDCl3, 600 MHz) 
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COSY spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin D (65) (CDCl3, 600 Mz) 
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HSQC (decoupled) spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin D (65) (CDCl3, 600 Mz) 
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HMBC spectrum of 10-bromo-6,7-dimethoxyhomofascaplysin D (65) (CDCl3, 600 Mz) 
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Appendix F 
10-Bromohomofascaplysin A Spectra 
 
1H NMR spectrum of 10-bromohomofascaplysin A (66) (CDCl3, 600 MHz) 
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13C NMR spectrum of 10-bromohomofascaplysin A (66) (CDCl3, 150 MHz) 
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COSY spectrum of 10-bromohomofascaplysin A (66) (CDCl3, 600 MHz) 
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HSQC (decoupled) spectrum of 10-bromohomofascaplysin A (66) (CDCl3, 600 MHz) 
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HMBC spectrum of 10-bromohomofascaplysin A (66) (CDCl3, 600 MHz
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